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ABSTRACT 
The Relationship between Pediatric 
Asthma and Obesity in Nevada 
By 
Jennifer Anne Lucas 
Asthma and obesity are two of the most common comorbid health problems in the U.S. Currently 
nearly 8% of Nevada youth are affected by asthma and more than 30% are overweight or obese. Obesity 
is a risk factor for asthma, yet asthma-related factors such as decreased physical activity and use of oral 
corticosteroids for asthma control can lead to obesity. This study examined the relationship between 
asthma and obesity in two pediatric populations in Nevada. It was hypothesized that children with asthma 
and elevated BMI would have more severe asthma symptoms, decreased lung function, poorer quality-of-
life measures, and different atopic profiles than those with a BMI in the healthy weight category. This 
was evaluated using pilot data collected from a University of Nevada, School of Medicine pediatric 
allergy/immunology clinic in Reno, NV. This study also evaluated whether or not a 12-week physical 
activity intervention is feasible to complete for pediatric overweight/obese who have asthma compared 
with overweight/obese without asthma. Weight loss in youth who have asthma has been shown to 
improve asthma control and lung function. Intervention data were obtained from medical records at the 
Children’s Heart Center (CHC) Nevada Healthy Hearts Program (HHP) in Las Vegas. Statistical analyses 
included descriptive statistics, multivariable binary and multinomial logistic regression, Cox regression, 
and one-way and repeated measures analyses of variance. The Reno population (N=125) had a median 
age of 7 years old, was 61% male, 65% white, and nearly one-third were overweight or obese. Main 
findings showed that obese youth with asthma had higher odds of having severe asthma than those at 
healthy weight, though not significantly higher (p=0.162). Lung function was not different among BMI 
percentile groups, yet those who were obese did have nearly 8 times higher odds of needing oral steroids 
for asthma control than those who were healthy weight (p=0.003). Children who were overweight had 
79% lower odds of allergen sensitization (aOR 0.21, p=0.010). The CHC population (N=232) had a mean 
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age of 11 years, 54% male, 64% Hispanic, and 37% had asthma. Crude analyses of the HHP population 
showed that BMI did decrease significantly among those with asthma (p=0.002) and without asthma 
(0.001) from pre- to post-intervention. Cardiorespiratory health increased significantly among girls 
(p=0.004) and boys (p=0.003) who have asthma, as well as among both girls (p=0.001) and boys 
(p=0.001) without asthma. Multivariable analysis demonstrated no difference in attrition between those 
with and without asthma (p=0.300), and no difference in weight loss (p=0.951) or cardiorespiratory health 
(males, p=0.263, females, p=0.655) between participants with and without asthma, indicating that this 
intervention was feasible for asthmatics to complete as a form of physical activity engagement and weight 
management. These results show that obese youth had poorer asthma control than healthy weight children 
as evidenced by oral steroid use at the initial visit to the clinic, and a high degree of allergen sensitization 
among the entire population, although lower among overweight children. It is important to make sure all 
children with asthma in Nevada are tested for allergen sensitization regardless of weight status. Mean 
BMI decreased and VO2 max increased indicating that this program was also beneficial in improving 
respiratory outcomes for youth who have asthma. Future studies may be conducted to expand this 
intervention in order to determine the efficacy of physical activity, weight reduction and lung function 
improvement among a larger clinical population of asthmatics. 
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CHAPTER 1. INTRODUCTION 
Purpose of the Study 
Asthma is a chronic inflammatory respiratory disease in which airflow to and from the lungs is 
restricted or limited. Asthma currently affects 300-334 million people worldwide, and in the United 
States, the disease burdens more than 25 million people, including nearly 7 million youth (those under 
age 18) (Asher & Pearce, 2014; Moonie, Seggev, Shan, Pergola, & Teramoto, 2014; National Heart, 
Lung, and Blood Institute [NHLBI], 2007; & NHLBI, 2014). Overweight and obesity are associated with 
the development of pediatric asthma. Additionally, obese people with asthma are more likely to have 
more asthma symptoms, more severe symptoms, and require increased healthcare utilization (Black, 
Zhou, Takayanagi, Jacobsen, & Koebnick, 2013; Dixon et al., 2010; Porter et al., 2012; Sutherland, 
2014). The current National Health and Nutrition Examination Survey (NHANES) data from 2011-2012 
show 31.8% of U.S. 2-19 year olds have a body mass index (BMI) at or above the 85
th
 percentile 
(considered overweight or obese), and 16.9% have a BMI at or above the 95
th
 percentile (obese) based on 
Centers for Disease Control and Prevention (CDC) growth charts (Ogden, Carroll, Kit & Flegal, 2014). 
While the literature has shown obesity is a risk factor for asthma (Dixon et al., 2010; NHLBI, 2007), 
factors related to asthma, such as decreased physical activity and use of corticosteroids for asthma control 
have also been found to be potential risk factors for developing overweight or obesity (Abd El-Kader, Al-
Jiffri, & Ashmawy, 2010; Lang, 2014; NHLBI, 2007).  
Atopy is a genetic predisposition to develop allergies (American Academy of Allergy, Asthma, & 
Immunology [AAAAI], 2015b). Allergies are present in the majority of those who have asthma 
(approximately 80%) (Cohn, Elias, & Chupp, 2004). In Nevada, very little research has been done 
regarding aeroallergen sensitization, but Wong, Wilson, Peele, and Hogan (2012) found youth in Nevada 
become sensitized at very young ages, and to allergens not seen in the rest of the country. Early 
sensitization can be a predictor of wheezing, which is a risk factor for asthma (Wong et al., 2012). 
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Analysis of NHANES data found outdoor aeroallergen sensitization is highest in the Western U.S. (Salo 
et al., 2014). 
Study Goals 
This study has two goals. The first is to examine relationships between asthma/allergy and 
obesity in two pediatric Nevada populations to determine how these two common conditions are 
associated with each other. It is hypothesized that pediatric asthma patients with high Body Mass Index 
(BMI) will have more severe asthma symptoms, decreased lung function, and poorer quality-of-life and 
financial cost measures compared to those who are at a healthy weight. It is also hypothesized that 
allergen sensitization as measured by skin prick tests will differ between those who have an elevated BMI 
and those at healthy weight. 
The second goal is to evaluate a 12-week physical activity intervention for pediatric patients to 
determine if it is feasible for overweight/obese youth with asthma compared to overweight/obese youth 
without asthma. It is hypothesized that the intervention may not be as feasible for those who have asthma 
due to respiratory stress, as measured by time in the program, as well as pre- and post- intervention 
clinical indicators. 
Significance of the Study 
 The unique arid climate and wind patterns in the Great Basin region, which includes both Reno 
and Las Vegas, contribute to the growth and dispersion of aeroallergenic flora not found in other areas in 
the U.S. These allergens can increase wheezing and other allergic symptoms that contribute to the 
development and exacerbation of asthma (Jewell & Nicoll, 2011; Wong et al., 2012).  
More than 20 states are included in the Centers for Disease Control and Prevention’s (CDC) 
National Asthma Control Program (NACP). Nevada is not one of the included states although the rates 
are comparable to the nation. The goal of the NACP is to help the “millions of people with asthma in the 
United States gain control over the disease” (CDC, 2015b). The NACP helps to improve asthma 
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surveillance at local and state levels, and to help educate people with asthma, and the general public about 
the disease. State level data are provided regarding treatment, management, and control of asthma (CDC, 
2015b). Until Federal funding becomes available for the addition of new states, Nevada does not have the 
opportunity to benefit from this federal-level surveillance and education. Consequently, asthma research 
is needed in Nevada until the occasion arises to work with the Nevada Division of Public and Behavioral 
Health (DPBH) to seek funding from the CDC’s NACP.  
Adult and adolescent overweight and obesity rates in Nevada are comparable to the national rates 
(Division of Nutrition, Physical Activity and Obesity [DNPAO], 2015). However, 4-6 year olds in 
Nevada have been found to have high rates of obesity: 19.0% of those entering kindergarten in 2013 were 
obese, up from 18.2% in 2012. In the past year, this number has increased: 21.7% of those entering 
kindergarten in 2014 were obese (Nevada Institute for Children’s Research and Policy [NICRP], 2014; 
NICRP, 2015). Data from the National Survey of Children’s Health shows that among Nevadans aged 10-
17 years, 18.6% are obese, which is slightly above the national average of 15.7% (Data Resource Center 
for Child and Adolescent Health [DRC], 2012). 
 Asthma and obesity are comorbid disorders, but since they are both complex disorders with 
multiple causes it is complex to understand if one actually causes the other. Obesity is a known risk factor 
for the development and severity of asthma (Dixon et al. 2010). Additionally, treatments that have been 
used for decades to control asthma are not always effective in those with elevated BMI (Forno et al., 
2011). 
 Weight loss has been shown to improve lung function, and asthma severity, yet asthmatic 
children who struggle with breathing during exercise are a complex population to implement successful 
exercise interventions. Young asthma patients tend to avoid physical activity and report that symptoms 
interfere with all types of physical activity. Additionally, parental restriction of exercise in children with 
shortness of breath is not uncommon (Ostrom et al. 2013; Wanrooij, Willeboordse, Dompeling & van de 
Kant, 2014; Westergren et al., 2015). However, when young asthmatics do lose weight symptoms 
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improve, including exercise-induced bronchoconstriction (EIB) (Abd El-Kader et al., 2010; van Leeuwen, 
Hoogstrate, Dulverman, & Thio, 2014).   
One of the objectives of this research project is to evaluate a pre-existing weight loss intervention 
among young patients with elevated BMI, and to determine if asthmatic youth with elevated BMI in 
Nevada can benefit and successfully complete the intervention. Previous studies have found exercise 
interventions are effective for weight loss for obese asthmatic youth It is important to determine the 
feasibility and efficacy of this intervention among a pilot population of children with asthma and elevated 
BMI in order to increase outreach to this clinical population. Asthma and obesity are two of the most 
common health problems that youth currently face. To our knowledge this research has not yet been 
attempted in Nevada. Finding a feasible intervention to moderate the high obesity and asthma rates in 
Nevada’s youth could bring awareness to Nevada, as well as assist in securing federal funding. 
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CHAPTER 2. LITERATURE REVIEW 
Asthma 
Pathophysiology 
 The word “asthma” originates from a Greek word meaning “to gasp for breath” or “to pant 
heavily” (McFadden, 2004). Asthma is a common chronic respiratory condition characterized by airway 
inflammation, obstruction, and hyperresponsiveness, with a number of symptoms including, but not 
limited to wheezing, breathlessness, and cough. The severity and recurrence of these signs and symptoms 
varies greatly among asthma patients (Asher & Pearce, 2014; Cohn, et al., 2004; NHLBI, 2007; NHLBI 
2014; & WHO, 2013).  Numerous genetic and environmental factors contribute to the development and 
progression of asthma. Asthma has two forms: allergic, which affects approximately 80% of those with 
asthma, and non-allergic which is primarily genetic in origin (Busse & Lemanske, 2001; Cohn et al. 
2004).  
Airway inflammation and airflow obstruction occur in all people with asthma. Limited airflow is 
caused by inflammation and changes in the airway, including bronchoconstriction, airway wall 
thickening, edema and excess mucus secretion, airway remodeling, and airway hyperresponsiveness. 
Bronchoconstriction is a narrowing of the airways in response to inflammation caused by inhaled irritants 
to smooth muscle (Novak & Bieber, 2003; NHLBI, 2007).  The walls of the airway thicken when mucus 
mixes with inflammatory cells, which leads to smaller airways, and edema. Airway remodeling refers to 
structural changes to the airway, including the thickening of airways walls and increases in tissue mass 
which can become permanent and cause decline in lung function. These structural changes are likely due 
to damage to structural cells after inflammatory responses (Busse & Lemasnske, 2001; Cohn et al., 2004; 
NHLBI, 2007). Inflammation and airway remodeling lead to airway hyperresponsiveness, an increased 
response to stimuli in which bronchoconstriction occurs (Cohn et al., 2004; NHLBI, 2007). 
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Irritants that cause inflammation can include many allergens. Allergic (or atopic) asthma is 
generally characterized by sensitization to allergens, positive skin-prick tests to specific allergens and 
elevated Immunoglobulin E (IgE) antibody levels in response to the allergens. Approximately 80% of 
asthmatics are allergic (Busse & Lamanske, 2001; Novak & Bieber, 2003; Cohn et al., 2004; Raedler et 
al., 2015).  IgE antibodies, which are responsible for allergic reactions, act together with inflammatory 
cells in the pathogenesis of allergic diseases and asthma (Galli & Tsai, 2012; NHLBI, 2007). Multiple 
inflammatory cells play roles in the development of airway inflammation, including mast cells, 
eosinophils, and lymphocytes. Inflammatory mediators, such as cytokines, (signaling proteins), also 
influence airway inflammation in asthma patients (NHLBI, 2007). 
Mast cells, which originate in bone marrow and travel to the mucosal areas of airways, have IgE 
receptors, to which IgE antibodies bind. After exposure to IgE antigens, the mast cells are activated and 
release bronchoconstrictor facilitators such as histamine, which elicit allergic reactions. Activation of 
mast cells can also occur without IgE, which may lead to exercise-induced bronchospasm (Busse & 
Lemanske, 2001; NHLBI, 2007).  Knock-in mouse studies have shown that IgE and mast cells are a factor 
in chronic airway inflammation, and in turn, may influence airway remodeling (Galli & Tsai, 2012). Mast 
cells also release cytokines, in this case to promote inflammation (NHLBI, 2007). 
The connection between asthma and eosinophils has been recognized since 1908, when a 
physician found excess quantities of eosinophils in the airways of patient who died of an asthma attack 
(Ellis, 1908). Eosinophils, which are markers for inflammatory activity and regulated by cytokines, are 
often found in greater numbers in the airways of those who suffer from asthma than those who do not 
have asthma (Cianchetti et al., 2013; NHLBI, 2007). Eosinophils are believed to be the primary effector 
cells in asthma and persistent airway inflammation, meaning they are likely the main cells to mediate the 
removal of antigens or other causes of inflammation (Coico & Sunshine, 2015; Grotta et al., 2013; 
NHLBI, 2007).  
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More recently, lymphocytes known as T helper 1 cells (Th1) and T helper 2 cells (Th2) have been 
associated with asthma (McFadden, 2004; Robinson, 2010). Th1 and Th2 cells are believed to play a role 
in airway inflammation. Specifically, Th1 cells produce regulatory cytokines and mediate anaphylactic 
reactions. Th2 cells produce cytokines that promote inflammation by activating effector cells involved in 
allergen response  (Busse & Lemanske, 2001; Coico & Sunshine, 2015). Th2 cytokine production may 
also lead to IgE antibody production, excess eosinophils, and development of airway hyperresponsiveness 
(Coico & Sunshine, 2015; NHLBI, 2007). Currently, research investigating T-cell subtypes and 
biomarkers with the goal of creating new asthma therapies targeting Th2 cytokines and inflammation is 
ongoing (Jia et al., 2012; Robinson, 2010). 
Pathogenesis and Risk Factors  
 The pathogenesis of asthma is complicated and not definitive. The main factors in asthma 
pathogenesis are genetics (or host factors) and environmental exposures. Asthma is known to have 
genetic factors, but there is very little literature regarding pathogenesis (NHLBI, 2007; Olin & Wechsler, 
2014). Candidate gene studies, in which researchers look for specific genes, and genome wide studies, in 
which entire genomes are examined, are approaches some researchers believe will help determine the 
pathogenesis of asthma. Additionally, twin studies have shown that asthma may be 60% heritable (Ober 
& Yao, 2011; Olin & Wechsler, 2014).  
Other genetic factors include innate and adaptive immunity. Innate immunity refers to the 
mechanisms of the immune system people are born with, which provide quick response to foreign agents 
in the body. Adaptive immunity occurs when specific antigens activate B and T cells. The adaptive 
immune system forms memory responses to these antigens to create immunity (Coico & Sunshine, 2015; 
NHLBI 2007).  Presently, immunological research on asthma pathogenesis includes Th1 and Th2 
cytokine profiles, and the “hygiene hypothesis.”  With regard to asthma, the hygiene hypothesis may 
show how the imbalance of Th1 and Th2 cytokines may explain high asthma prevalence in developed 
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countries (Asher, 2014; NHLBI, 2007). This cytokine balance weighs protective factors, which favor Th1 
phenotype against allergic diseases, which favor Th2 phenotype (Figure 1) (Busse & Lemanske, 2001; 
NHLBI, 2007). Robinson (2010) discusses the hygiene hypothesis using animal models, which have 
shown cytokines, rather than antigens activate certain memory T cells during some infections, which may 
explain why infections early in life can protect against allergic diseases. Epigenetic studies have shown 
changes in Th1 and Th2-associated genes after allergen exposure in mice (Olin & Wechsler, 2014). 
 
 Multiple environmental factors are associated with the development and severity of asthma. 
Allergens are associated with asthma – for example, some research has shown exposure to pets at early 
ages is protective, but other studies have shown the opposite. Other allergens have been shown to be risk 
factors for development of asthma, such as cockroaches, and dust mites (NHLBI, 2007). Approximately 
20% of asthma diagnoses can be attributed to severe respiratory syncytial virus (RSV) in infancy, 
according to Olin & Wechsler (2014). Viral respiratory infections such as parainfluenza virus and some 
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rhinoviruses can also be risk factors for wheeze or asthma. Other possible risk factors for asthma include 
tobacco smoke and pollution (NHLBI, 2007; Ober & Yao, 2011). 
 Sociodemographic factors are also risk factors for developing asthma. Boys have higher risk for 
asthma than girls, however in adulthood, women are more likely to have asthma than men (NLHBI, 
2014). Some research shows youth who live in urban areas (“inner-city”) have higher risk for asthma due 
to more frequent exposure to respiratory infections from over-crowding, poor nutrition, and indoor air 
pollution, although socioeconomic status (SES) likely plays a larger role than urban or rural living in the 
development of asthma (Keet et al., 2015; Priftis, Mantzouranis, & Anthracopoulos, 2009).  
Asthma risk also differs with regard to race and ethnicity in the U.S.  Puerto Rican youth have the 
highest rates of asthma among any race or ethnicity in all U.S. states and territories (American Lung 
Association, 2011; Lara, Akinbami, Flores, & Morgenstern, 2006; Lara, Ramos-Valencia, Diaz, Reyes, & 
Gonzalez-Gavillán, 2014). Asthma prevalence rates are highest in Puerto Rican Island-born youth and 
Puerto Rican youth born in the contiguous states (Cohen et al. 2007; Keet et al., 2015; Lara et al. 2006). 
Black non-Hispanic youth also have higher risk of asthma compared to white non-Hispanics and 
Mexican-American youth (Akinbami, Moorman, & Liu, 2011; Keet et al., 2014; NHLBI, 2007). 
Allergy and Atopy as Predictors for Asthma 
Asthma is an allergic disease in approximately 80% of cases (Cohn et al., 2004; Novak & Bieber, 
2003). The allergic triad is the association between asthma, allergic rhinitis (hay fever), and atopic 
dermatitis. These three conditions occur early in childhood, beginning with atopic dermatitis, and then 
allergic rhinitis and asthma – this orderly fashion of allergic manifestations is known as atopic march 
(Ober & Yao, 2011). Sensitization to two or more allergens is known as polysensitization (Migueres et al. 
2014). Salo and colleagues found that allergen sensitization to outdoor aeroallergens, in particular grasses 
and Russian thistle weeds, is highest in the Western U.S. after analyzing NHANES data from 2005-2006 
(Salo et al., 2014). 
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Wheezing is a risk factor for the development and exacerbation of asthma (Asher, 2014; Wong et 
al., 2012) Martinez et al., (1995) found in a prospective cohort study, the Tucson Children’s Respiratory 
Study, that those with persistent wheezing within the first 9 months of life had significantly elevated IgE 
levels, however those levels were not associated with wheezing later in life. They also found some infants 
who wheeze might be predisposed to developing asthma (Martinez et al. 1995). Using data from the same 
longitudinal study, Castro-Rodriguez, Holberg, Wright, & Martinez (2000) created an Asthma Predictive 
Index to define risk of developing asthma in children who had persistent wheezing in the first three years 
of life. The index included wheezing, and one major risk factor or two-three minor risk factors. Major risk 
factors included parental history of asthma or eczema. Minor risk factors included eosinophilia, wheezing 
between colds, and allergic rhinitis (Castro-Rodriguez et al., 2000). They were able to predict asthma 59-
76% of the time, and the specificity of the index was more than 95% (Castro-Rodriguez et al., 2000). The 
Asthma Predictive Index, as well as other predictive indices, which were later developed, are currently 
used to try to determine whether a child will develop asthma (Castro-Rodriguez, 2010). 
Clinical Presentation of the Disease 
 Asthma symptoms are different for each person, and they vary in severity and occurrence. The 
most common symptoms are wheeze, shortness of breath, tightness in the chest, and cough. Common 
asthma symptoms are more likely to occur at night or early in the morning, or during physical activity, 
and are due to airway inflammation and changes to the airway, as mentioned above (NHLBI, 2007; 
NHLBI, 2014; WHO, 2013). These airway changes manifest by hyperplasia (increased tissue due to 
increased cell production) and hypertrophy (increased muscle size) of the airway wall smooth muscle, 
edema and excess mucus, permanent structural changes, bronchoconstriction (narrowing of the airways 
due to stimuli response), and airway hyperresponsiveness (Novak & Bieber, 2003; NHLBI, 2007).  
When symptoms become more intense or more symptoms occur acutely, this is known as 
exacerbation (also called an asthma attack). This acute presentation of symptoms leads to swelling in 
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airways and bronchospasm, which require emergency bronchodilator medication. As symptoms increase 
they can also worsen, and exacerbations can be fatal (NHLBI, 2007; NHLBI, 2014; WHO, 2013). 
Common triggers for asthma symptoms and exacerbations include indoor and outdoor allergens (dust 
mites, pollens, mold, pet dander, cockroaches), exercise, environmental tobacco smoke, air pollution, and 
chemicals (NHLBI, 2007; WHO, 2013). 
Diagnosis 
 Asthma is an under-diagnosed illness, especially in young people (Bitsko, Everhart & Rubin, 
2014; NHLBI, 2007; WHO, 2013). However, it can also be misdiagnosed in youth who have exercise-
induced shortness of breath or non-asthmatic wheeze or cough (Bitsko et al., 2014; NHLBI, 2007). 
Asthma diagnoses can also vary among populations and locations due to factors such as awareness of the 
disease, medical training, and cultural factors (Asher & Pearce, 2014). Asthma has no single cause; 
therefore, diagnosis is based on multiple factors including physical examination and clinical presentation 
of symptoms, medical history, and pulmonary function tests (Hargreave & Nair, 2009; NHLBI, 2007; 
Ober & Yao, 2012).   
The Guidelines for the Diagnosis and Treatment of Asthma, Expert Panel Report 3 (EPR-3) is a 
guide for medical professionals in clinical practice of asthma care. The National Heart Lung and Blood 
Institute (NHLBI) and National Asthma Education and Prevention Program (NAEPP) coordinated the 
development of the report, and commissioned an expert panel (NHLBI, 2007).  For the 3
rd
, most current 
revision of the report the expert panel conducted a current systematic review of the literature to reflect the 
greater understanding of asthma, and newer approaches to treatment since the previous version. The 
expert panel also updated recommendations for clinicians (NHLBI, 2007). 
To diagnose asthma, clinicians will determine whether or not airway obstruction symptoms exist, 
determine whether or not the obstruction is at least partially reversible, meaning the airways respond to 
bronchodilator medication, and exclude other (differential) diagnoses. A number of indicators may be 
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considered for an asthma diagnosis: wheezing, increased or worsening symptoms in the presence of 
multiple triggers (allergens, air pollutants, physical activity, weather, emotional exposure) or at night, as 
well as history of recurring cough, tightness in the chest, and difficulty breathing (NHLBI, 2007). Atopic 
dermatitis is not considered to be a key indicator in asthma diagnosis, but may increase the probability of 
an asthma diagnosis. Medical history can also help in diagnosing asthma as noted above with recurring 
symptoms. Family history of allergy and asthma is important, since asthma is known to be somewhat 
genetic (NHLBI, 2007; Olin & Wechsler, 2014). 
Pulmonary function tests (spirometry) are also used in diagnosis of asthma. These tests provide an 
objective, quantitative measure for airway obstruction by using a tool called a spirometer to test how 
much and how fast air can be inhaled and exhaled before and after use of a bronchodilator (NHLBI, 
2014). Spirometry measurements used include forced expiratory volume in 1 second (FEV1), the ratio of 
forced expiratory volume and forced vital capacity (FEV1/FVC), and forced expiratory volume in 6 
seconds (FEV6) (Hargreave & Nair, 2009; NHLBI, 2007). FEV1 is used to measure large airway volume 
(Spaulding, Devine, Duncan, Wilson & Hogan, 2012). FVC is the maximum volume of air that can be 
exhaled, however FEV6 has been shown to be nearly equivalent to FVC in measuring airway obstruction, 
and is used in older adults who need a longer time to exhale. Bronchodilators (such as short acting beta-
agonists [SABA]) are used to determine reversibility of obstruction to measure lung function growth and 
loss (NHLBI, 2007).  
NHLBI guidelines recommend using spirometry to measure lung function in children age 5 and older. 
However, literature has shown established reference ranges do not always measure pulmonary function 
well in youth, and diagnosis and treatment for those aged 5-18 should be based on frequency and severity 
of symptoms and exacerbations first (NHLBI, 2007).  
In the 1960s, the European Community for Coal and Steel (ECCS) developed spirometric reference 
value recommendations for occupational health measures. In 1970s, the first values for children and 
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adolescents were developed (Quanjer, Stanojevic, Stocks, & Cole, 2012b). There are currently a number 
of reference equations available to determine normal ranges. Normal or baseline values are based on 
predicted values, which take into account the variables age, height, race/ethnicity, and gender. Personal 
best values may also be used as reference for those with known pulmonary function problems (AAAAI, 
2014; “Pulmonary function tests,” 2013; Quanjer et al., 2012a; Simon et al., 2010). The most recently 
developed reference equation is the Global Lung Function Initiative (GLI) 2012 equation (Quanjer et al., 
2012a). Two experts on pulmonary function were consulted by the AAAAI regarding reference equations. 
One expert recommended GLI 2012 equations if possible. The other expert stated that reference equations 
can be controversial and said that while there are advantages to the GLI equations, other equations are 
also good, and to choose based on the practice and population (AAAAI, 2014). 
Although it is not the only reference equation available to clinicians, multiple associations and 
societies worldwide, including the American Thoracic Society (ATS), have endorsed the GLI equation 
from Quanjer et al. (2012). The final equation for predicted value, based on more than 160,000 datapoints 
from 33 countries is a regression equation which uses an LMS method to take into account the mean 
(mu), coefficient of variation (sigma), and skewness (lambda): 
log(Y) = a + b•log(H) + c•log(A) + age-spline + d•group 
in which Y=dependent variable, H=height standing in centimeters, A = age in years, a, b, c, and d are 
coefficients, spline is an age-adjustment to correct for age between 3 and 95 years and to correct skew if 
necessary. Group is a dummy variable (0 or 1) to adjust for race (Caucasian, African American, North or 
South East Asian) (Quanjer et al., 2012). Lower limits of normal are also calculated, as well as z-scores to 
determine deviation from the mean (Merkus, 2014). However, in everyday practice, percent predicted is 
often used to determine lung function (Table 1). NHLBI Guidelines do not have spirometry measures for 
those under age 5. For those age 5-11 with intermittent asthma severity, FEV1 is normal between 
exacerbations, and >80% predicted, and FEV1/FVC is >85%; for those aged 5-11 with mild persistent 
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asthma, FEV1 is ≥80% predicted, and FEV1/FCV is >80%; for those age 5-11 with moderate persistent 
asthma, FEV1 is 60-80% predicted, and FEV1/FVC is 75-80%; and for those age 5-11 with severe 
persistent asthma FEV1 is <60% predicted and FEV1/FVC is <75% (Table 1). For those age 12 and older 
with intermittent asthma severity, FEV1 is normal between exacerbations, FEV1 is >80% predicted, and 
FEV1/FVC is also normal; for those age ≥12 with mild, persistent asthma, FEV1 is ≥80% predicted, and 
FEV1/FVC is normal; for those age ≥12 with moderate, persistent asthma severity, FEV1 is >60%, but 
<80% predicted and FEV1/FVC is reduced 5%; and for those ≥12 with severe, persistent asthma, FEV1 
<60% predicted, and FEV1/FVC is reduced >5% (Table 1). In addition to spirometry, peak expiratory 
flow, which is the speed of exhalation, may be tested with a peak flow meter. Ranges are based on 
standardized rates and the patient’s own rate (ALA, 2016). The NHLBI does not recommend peak 
expiratory flow as a diagnostic tool over spirometry, rather it should be used for monitoring of asthma 
(NHLBI, 2007). 
Diagnosis of other illnesses that have similar symptoms to asthma, such as pneumonia or chronic 
obstructive pulmonary disorder (COPD) must also be ruled out (Asher & Pearce, 2014, NHLBI, 2007). 
These diseases differ for children and adults. For infants and children, upper airway diseases, such as 
allergic rhinitis, obstructions involving the large (e.g. vocal cord dysfunction) or small airways (e.g. cystic 
fibrosis), and other causes, such as cough not due to asthma, must be considered. Other diagnostic 
possibilities for adults include conditions such as COPD, vocal cord dysfunction, or pulmonary embolism 
(NHLBI, 2007). 
Classification of Severity  
 Treatment of asthma is dependent upon the severity of the disease, which is assessed in terms of 
impairment and risk. Asthma may be intermittent or persistent, and mild, moderate or severe. Before the 
most current (2007) NHLBI Guidelines for the Diagnosis and Treatment of Asthma, “intermittent” was 
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called “mild intermittent”, however this was changed since those who have intermittent asthma may still 
have moderate or severe exacerbations (NHLBI, 2007).  
Impairment consists of 1) symptoms (which include quality-of life factors such as being woken 
up, need for SABAs, missed work or school, and ability to do everyday activities) and 2) lung function 
measured by spirometry (NHLBI, 2007). In 2007, prominence was put on using FEV1/FVC instead of 
FEV1 for assessment of severity in children because it may be a more sensitive measure of lung function 
(NHLBI, 2007). However, current research supports using forced expiratory flow at 25-75% (FEF25-75%), 
as it is a more sensitive measure of lung function, especially in children. Low FEF25-75% in children is 
associated with poorly or uncontrolled asthma (Duncan et al., 2012; Simon et al, 2010). Simon et al. 
(2010) found that even when FEV1 was normal, FEF25-75% detected airway obstruction. An FEF25-75% 
increase of 30% from baseline after bronchodilator medication is considered clinically significant. 
However if the baseline is below normal range, and the increase moves FEF25-75% into the normal range 
after bronchodilator, the change is also considered successful, and clinically significant, even if it is below 
a 30% change (Spaulding et al., 2012). Ciprandi and colleagues also support using FEF25-75% in children, 
as it is more sensitive and FEV1 may appear normal in those with mild asthma. An FEF25-75% value of less 
than 65% of the predicted value is considered to be abnormal (Ciprandi et al., 2012) 
 Assessment of risk refers to the prediction of risk of events such as exacerbations and death, 
which is based upon frequency of exacerbations needing oral steroid therapy, severe airflow obstruction, 
persistent severe airway obstruction, emergency department or hospitalizations, fear of asthma (as 
perceived by the patient), demographic, socioeconomic, and psychosocial factors (NHLBI, 2007). Table 1 
(adapted from NHLBI, 2007 guidelines), shows classification of asthma severity in children and adults. 
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Table 1. Classification of Severity by Impairment & Risk in Patients Not Medicated for Long-
Term Control (all ages) (adapted from NHLBI, 2007) 
Severity Components 
Classification of Asthma Severity 
Age* Intermittent
a
 
Persistent 
Mild Moderate Severe 
Im
p
a
ir
m
e
n
t 
Symptoms 
0-4y 
≤2 days/week 
>2 d/week 
but not daily 
Daily 
Throughout 
the day 
5-11y 
≥12y 
Nighttime 
awakenings 
0-4y 0 1-2x/month 3-4x/month >1x/week 
5-11y 
≤2x/month 3-4x/month 
>1x/week but 
not nightly 
Often 
7x/week ≥12y 
SABA** use  
for symptom 
control *** 
0-4y 
≤2 days/week 
>2 d/week 
but not daily 
Daily 
Several 
times/day 5-11y 
≥12y 
≤2 days/week 
>2 d/week 
but not >1x/d 
Daily 
Several 
times/day 
Interference 
with normal 
activity 
0-4y 
None 
Minor 
limitation 
Some 
limitation 
Extremely 
limited 
5-11y 
≥12y 
Lung function† 0-4y n/a‡ n/a n/a n/a 
5-11y  Normal FEV1 
between 
exacerbations  
 FEV1 >80%   
 FEV1/FVC 
>85% 
 FEV1 ≥80% 
predicted 
 FEV
1
/FVC 
>80% 
 FEV1 >  
60-80% 
predicted 
 FEV1/FVC 
 75-80% 
 FEV1 <60% 
predicted 
 FEV1/FVC 
<75% 
≥12y  Normal FEV1 
between 
exacerbations  
 FEV1 >80% 
predicted  
 FEV1/FVC 
normal 
 FEV1 ≥80% 
predicted 
 FEV1/FVC 
normal 
 FEV1 >60% 
but <80% 
predicted 
 FEV1/FVC 
reduced 5% 
 FEV1 <60% 
predicted 
 FEV1/FVC 
reduced 
>5% 
R
is
k
 
Exacerbations 
requiring oral 
systemic 
corticosteroids 
0-4y 
0-1/year 
≥2 exacerbations in 6 months requiring oral 
steroids or ≥4 wheezing episodes/ 1y lasting 
>1d AND risk factors for persistent asthma 
5-11y ≥2 in 1 year 
≥12y ≥2/year 
     Adapted from NHLBI, 2007,pp.72-74 (http://www.nhlbi.nih.gov/files/docs/guidelines/04_sec3_comp.pdf) 
* Age ≥12y = 12 through adulthood 
** Short-acting β2-agonist  
*** Not including SABA use for exercise-induced bronchospasm 
† Normal FEV1/FVC: 8-19 yr 85%; 20-39 yr 80%; 40-59 yr 75%; 60-80 yr 70% 
‡ n/a = not applicable 
a Intermittent was formerly classified as “Mild Intermittent.” Now, “Intermittent” severity is classified as 
one category as intermittent asthma is not always mild, it can also be moderate or severe. However, the 
intermittent severity classification is not broken into the three severity levels (mild, moderate, severe) 
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Treatment and Management 
 After the diagnosis and classification of severity of asthma, the patient will begin treatment. 
Rather than using severity measures to assess whether or not treatment is working, asthma control, or day-
to-day symptom management, is to be assessed and monitored. Asthma control is also defined in terms of 
reducing impairment and risk. Risk refers to having or not having exacerbations (NHLBI, 2007).  
Components of asthma control impairment include the same components as severity (Table 1), and in 
youth age 12 or older and adults, also include a validated questionnaire such as the Asthma Control 
Questionnaire, the Asthma Therapy Assessment Questionnaire, the Asthma Control Test, or the Asthma 
Control score (NHLBI, 2007). 
Long-term management of asthma includes control of asthma (reduction of impairment risk), 
which is achieved by pharmacotherapy, as well as monitoring and follow-up (NHLBI, 2007; Reddy, 
Doshi, Covar, & Spahn, 2014). Doctors are encouraged to work with their patients or patients’ parents to 
form Asthma Action Plans, which are written plans that address the daily management of asthma, such as 
medications and avoiding triggers, and how to identify and cope with the worsening of the disease. The 
identification and management of decreased asthma control includes items such as peak flow meter use 
and ranges, knowing which emergency medications to take, where to find emergency phone numbers, and 
which signs and symptoms indicate asthma is worsening (NHLBI, 2007).  
Long-Term Pharmacotherapy  
There are a number of types of medications used in the long-term management of asthma, 
including: corticosteroids (inhaled and oral, depending on severity of symptoms), cromolyn sodium and 
nedocromil, immunomodulators, leukotriene modifiers, long-acting beta2-agonists (LABAs), 
methylxanthines, and the long-acting muscarinic antagonist (LAMA), tiotropium. Medication is 
prescribed by age (0-4, 5-11, ≥12 to adult), and in a stepwise approach, in that medication doses/types are 
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increased or decreased as asthma control worsens or improves (NHLBI, 2007; Olin & Wechsler, 2014; 
Reddy et al., 2014).  
Corticosteroids reduce inflammation. Inhaled corticosteroids (ICS) are commonly used as long-
term therapy for persistent asthma (Duncan et al., 2012; NHLBI, 2007). The use of long-term oral steroids 
for asthma began in the 1950s. This practice has been decreasing, due in part to newer, more potent ICS’s, 
and more knowledge of adverse effects attributed to long-term use of older steroids, however, oral 
corticosteroids are still used in severe cases of persistent asthma (Reddy et al., 2014; NHLBI, 2007).   
Cromolyn sodium and nedocromil work by stabilizing mast cells, which play a role in allergic 
response, and are used with mild persistent asthma when other medications are not available, or do not 
work (NHLBI, 2007). Some forms of cromolyn and nedocromil inhalers were discontinued in the U.S. in 
2010 due to their contribution to ozone layer depletion (Food and Drug Administration [FDA], 2010).  
For mild asthma, immunomodulators, which are antibodies that prevent binding of IgE to pro-
inflammatory cells, and have been shown to decrease exacerbations (Olin & Wechsler, 2014). 
Leukotriene modifiers are antagonists to mediators (leukotrienes) released from inflammatory cells, and 
are often used as a back up to ICS therapy. Methylxanthines may have anti-inflammatory effects and may 
be used with ICS, but are not commonly prescribed due to safety issues such as seizures (NHLBI, 2007).  
LABAs are bronchodilators given as the preferred treatment in combination with ICS for patients 
age 12 and older, and with ICS in children age 0-11 with moderate-severe asthma. LABA/ICS 
combination therapy has been shown to improve control and decrease exacerbations and hospitalizations 
(NHLBI, 2007; Reddy et al. 2014). Additionally LAMAs may be used in combination with ICS or ICS 
and LABAs in those over age 12 with moderate to severe asthma. LAMAs work in the smooth muscle 
tissue (Lipworth, 2014). 
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Short-Term (Relief) Medications 
 SABAs are the preferred treatment for acute bronchoconstriction. They have been shown to 
improve symptoms, hyperresponsiveness, quality of life, and lessen the frequency of exacerbations 
(NHLBI, 2007; Olin & Wechsler, 2014). Anticholinergics are relief medications that act by blocking 
acetylcholine neurotransmitters from binding to receptors, which are responsible for involuntary muscle 
constriction, and in turn relaxing smooth muscle airway constriction. They may be used with SABAs or 
as an alternative. Oral systemic corticosteroids may also be used for severe exacerbations (NHLBI, 2007).  
Safety of Corticosteroids 
As noted earlier, long-term, systemic first-generation corticosteroid use has been associated with 
negative effects such as suppression of growth and adrenal suppression, osteoporosis, hypertension, and 
myopathy, a disease of the skeletal muscles due to cell structure and metabolic dysfunction, which leads 
to muscle weakness. Additionally, long-term use of oral corticosteroids can increased risk of Cushing’s 
syndrome (McFadden, 2004; Reddy et al., 2014; Cleveland Clinic, 2015). Cushing’s syndrome is an 
endocrine disorder of the adrenal glands, which secrete cortisol as a metabolic function. In Cushing’s 
syndrome there is too much cortisol – such as when corticosteroids are being used in high doses. The 
extra cortisol leads to increased insulin production and secretion, and glucose production (Nussey & 
Whitehead, 2001).  Insulin and glucose lead to extra fat production, which is distributed around the 
abdomen, while the muscles in the limbs, shoulders and hips experience myopathy, and weakness. Those 
with Cushing’s syndrome often develop “moon face” meaning the face becomes very full and round due 
to fat distribution on the sides of the face. Diabetes and impaired glucose tolerance may also occur 
(Nussey & Whitehead, 2001). First-generation corticosteroids required higher doses that led to the 
adverse effects noted earlier. Newer second-generation corticosteroids are more potent, so they require 
smaller doses. Additionally the addition of LABAs can decrease steroid doses even further, and still 
provide asthma control and decreased exacerbations (Reddy et al. 2014). However, there is a possibility 
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that even inhaled corticosteroids may be associated with growth suppression, and it is recommended that 
linear growth be observed in all youth (Castro-Rodriguez, Custovic, & Ducharme, 2016). 
Asthma Prevalence 
Worldwide Morbidity  
Globally, 300-334 million people currently have asthma (Asher & Pearce, 2014; NHLBI, 2014). 
The International Study of Asthma and Allergies in Children (ISAAC), a standardized data collection 
project from 105 countries, contributed data for the Global Burden of Disease Study (GBD) 2010. The 
GBD 2010 showed infectious diseases are decreasing worldwide, and chronic respiratory conditions 
currently contribute to increasing disability rates (Asher & Pearce, 2014). Disability-adjusted life years 
(DALYs) are used by the GBD to measure the burden of disease by looking at the absolute health lost 
from disease, including mortality and years lived with the disease to determine healthy years of life lost. 
In 2010, asthma was the 8
th
 highest cause of DALYs in youth age 5-9, 3
rd
 highest in those 10-14, and 12
th
 
for those aged 15-19, globally.  
United States Morbidity  
In the U.S., asthma burdens more than 25 million people, including nearly 7 million children 
(Asher & Pearce, 2014; Moonie et al., 2014; NHLBI, 2014). Consistent with risk factors for asthma, 
Behavioral Risk Factor Surveillance System (BRFSS) asthma prevalence data, show that among youth in 
the U.S., males have significantly higher rates of lifetime and current asthma (lifetime: 16.3%, current: 
9.2%) than females (lifetime: 11.8%, current: 8.0%). Adult males have significantly lower asthma rates 
(lifetime: 11.7%, current: 6.3%) than adult females (lifetime: 16.2%, current: 11.5%) (Table 2) (CDC, 
2015a). The BRFSS is a random-digit-dialed telephone survey conducted in all U.S. states, Washington 
D.C. and three territories. Two questions are asked about asthma to obtain current and lifetime rates. The 
data are self-reported by adults, and by proxies for participants under the age of 18 using the Childhood 
Asthma Module (CDC, 2015a). 
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Table 2.  2013 Lifetime & Current Weighted Asthma Prevalence for Youth and Adults in 
the United States by Sex  
 All Male Female 
 N % 
(95%CI)* 
N % 
(95% CI) 
N % 
(95% CI) 
Youth  
  (0-17) 
All Male Female 
  Lifetime 65,835 14.0 
(13.5-14.6) 
33,751 16.3 
(15.5-17.1) 
31,383 11.8 
(11.1-12.6) 
  Current 65,559 9.2 
(8.8-9.6) 
33,607 10.4  
(9.8-11.1) 
31,295 8.0 
(7.4-8.6) 
Adults All Male  Female 
  Lifetime 482,317 14.0 
(13.8-14.2) 
197,569 11.7 
(11.4-12.0) 
284,748 16.2 
(15.9-16.5) 
  Current 480,460 9.0 
(8.8-9.1) 
196,859 6.3 
(6.1-6.5) 
283,601 11.5 
(11.2-11.7) 
Adapted using 2013 BRFSS data (http://www.cdc.gov/asthma/brfss/2013/default.htm) 
*CI = confidence interval 
 
Race and ethnicity also affect asthma prevalence in the U.S. The National Health Interview 
Survey (NHIS) is an annual, in-person survey conducted by the National Center for Health Statistics at 
the CDC using a representative sample of the U.S. population. Data are weighted and standard error is 
reported with prevalence estimates to account for sampling error (CDC, 2016b). NHIS lifetime asthma 
prevalence rates for 2013 show that among all those under 18 years of age, black non-Hispanic youth 
have the highest rates of asthma (18.9%), until the Hispanic categories are stratified by Mexican/Mexican 
American (11.8%) and Puerto Rican (31.3%) (Figure 2) (CDC, 2016b). 
 
Figure 2. Rates of Lifetime Asthma by Race/Ethnicity, Ages <18, 2014, U.S. 
Adapted from 2014 National Health Interview (NHIS) data (http://www.cdc.gov/asthma/nhis/2014/table2-1.htm) 
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Numerous studies found high prevalence of asthma among Puerto Rican youth in the U.S. with 
lifetime rates as high as 41.3% and 44% in those living in Puerto Rico (Cohen et al., 2007; Lara et al., 
2014), and 35.3% for those living in the 50 states (Cohen et al., 2007). In recently published research, 
Keet et al. (2015) sought to examine how asthma predictors such as inner-city living, poverty levels, and 
race/ethnicity affected the prevalence of childhood asthma by linking 2009-2011 NHIS data to U.S. 
Census tract data from the NCHS. The authors found significantly higher rates of asthma in Puerto Rican 
children (adjusted Odds Ratio [aOR] = 2.38, 95% Confidence interval [CI] [1.82-3.11]) and black 
children (aOR = 1.87, 95% CI [1.59-2.19], compared to white children, after adjusting for age, sex, 
geographic region, urban or rural area, neighborhood-level poverty, and birth outside the U.S (Keet et al. 
2015). These finding are consistent with the literature (Dorevitch et al., 2013; Lara, et al., 2006; Olin & 
Wechsler, 2013).  
 Nevada Morbidity  
 In Nevada, the childhood asthma rates are comparable among males and females for both current 
and lifetime asthma in pooled 2011-2014 data. Rates are highest in Washoe County (lifetime: 11.5%, 
current: 7.2%). Those aged 10-14 years had the highest lifetime and current rates from 2011-2014 
(lifetime: 14.8%, current: 8.1%) (Table 3) (Moonie & Lucas, 2016). Black children have the highest rates 
of all race/ethnicities; the lifetime rate was 15.8% and the current rate was 7.0% (Table 3) (Moonie & 
Lucas, 2016). 
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Table 3. Nevada Lifetime/Current Weighted Asthma Prevalence: Ages 0-17 (Pooled 2011-2014 data) 
 Lifetime Asthma Current Asthma 
Demographic Grouping N % (95%CI) N % (95% CI) 
Statewide Nevada 4,195 10.1 (8.7-11.4) 4,036 6.2 (5.1-7.2) 
Region Clark County 1,502 10.4 (8.6-12.2) 1,498 6.0 (4.6-7.3) 
Washoe County 1,363 11.5 (9.3-13.8) 1,357 7.2 (5.4-9.1) 
Balance of State 1,172 10.8 (8.5-13.1) 1,165 6.1 (4.5-7.8) 
Age 0 – 4 416 5.7 (2.2-9.3) 414 3.7 (0.4-6.9) 
5 – 9 918 9.8 (7.1-12.6) 914 5.9 (3.7-8.1) 
10 – 14 1,167 14.8 (11.8-17.8) 1,162 8.1 (6.0-10.2) 
15 – 17 844 12.3 (8.7-15.8) 839 6.1 (3.8-8.5) 
Sex Boy 2,044 12.0 (10.0-14.0) 2,033 6.5 (5.0-8.0) 
Girl 1,938 9.6 (7.6-11.6) 1,932 6.1 (4.5-7.6) 
Race/Ethnicity Asian 106 6.9 (1.2-12.6) 106 4.2 (0.1-8.4) 
Black 187 15.8 (9.5-22.0) 185 7.0 (3.0-10.9) 
Hispanic 1,036 10.1 (7.6-12.5) 1,033 6.2 (4.2-8.2) 
White 2,402 10.3 (8.5-12.1) 2,391 6.5 (5.1-7.9) 
Other 276 11.6 (6.3-17.0) 275 4.3 (1.7-6.9) 
Adapted from Moonie & Lucas, 2016 
 
 
Mortality  
 Each year there are approximately 250,000 deaths from asthma worldwide. In the U.S., the 
mortality rate for asthma is 1.1 per 100,000, and 3,600 people in the U.S. died from asthma in 2013 
(AAAAI, 2015a; CDC, 2015c). The use of inhaled corticosteroids has decreased asthma mortality, though 
in the U.S., women are still 30% more likely to die from asthma than men, and the risk of death is 75% 
higher for black people than for white people (Olin & Wechsler, 2014). 
Asthma Costs 
Financial Costs 
In 2007, asthma costs in the U.S. were approximately $56 billion (Barnett & Nurmagambetov, 
2011; Moonie et al. 2014). Barnett & Nurmagambetov (2011) estimated direct costs and loss-of-
productivity costs, for the years 2002-2007 in 2009 U.S. dollars, and found the pooled estimates of direct 
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costs per year for a person with asthma was $3,259, which factored in outpatient hospital visits 
($151/year), inpatient hospitalizations ($446/year), and ED visits ($110/year). Doctor’s office visits were 
estimated to be $581 per year, and medications for asthma control were predicted to be $1,680/year. 
Additionally, loss of workdays was estimated to cost $301 and loss of school days $93 per year (Barnett 
& Nurmagambetov, 2011). The estimated deaths due to asthma cost $2.37 billion/year, or $14.25 billion 
for 2002-2007 (Barnett & Nurmagambetov, 2011). From 2009-2011, more than 439,000 to 500,000 
asthma patients required hospital admission annually, and more than 2 million required ED visits. 
Hospital stays averaged 3.6 days (CDC, 2015c; Olin & Wechsler, 2014). Regionally, Moonie, et al., 2014 
found asthma patients age 0-17 in Southern Nevada required significantly more ED use than adults, and 
the youth population also required more hospitalizations and primary care visits than adults with asthma. 
Furthermore, black people were 2.5 times more likely to need ED treatment and hospitalizations in 
Southern Nevada (Moonie et al. 2014). 
Quality-of-Life  
In addition to increased healthcare use and cost, asthmatic patients also have lowered quality-of-
life than non-asthmatic patients as symptoms can worsen, and make it impossible to participate in usual 
activities and go to work and school. Children with asthma are more likely to be absent from school than 
those who do not have asthma (Asher & Pearce, 2014; Moonie, Sterling, Figgs, & Castro, 2008; Olin & 
Wechsler, 2014). In 2008, Moonie et al. found that although children with persistent asthma missed more 
school and had lower standardized test scores, those with asthma could still succeed academically as well 
as those without asthma (Moonie et al. 2008). 
Obesity 
Pathophysiology and Pathogenesis 
Overweight or obesity is defined as an amount of adipose tissue greater than the ideal amount for 
healthy weight. Body mass index (BMI), calculated from weight and height measurements, is currently 
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considered to be an accepted and reliable way to categorize weight status in adults and children (CDC, 
2014; Waters et al., 2011).  
Adipose tissue is composed of adipocytes and other cells, such as pre-adipocytes, immune cells 
(such as macrophages), stem cells, muscle cells, and blood cells. The human body can efficiently store 
extra fat, which is needed if starvation occurs, but when more calories are consumed than expended 
(positive caloric balance), adipocytes can become dysfunctional (Capurso & Capurso, 2012; Redinger, 
2007). During normal positive caloric balance, new adipocytes are created due to signaling of pre-
adipocytes for proliferation and differentiation into adipocytes. When there is too much caloric 
imbalance, adipocyte dysfunction occurs, visceral fat accumulates and releases inflammatory cytokines 
called adipocytokines, or adipokines. Additionally, fatty acids are released from adipocytes, and taken up 
by adipose and non-adipose tissue, leading to obesity (Capurso & Capurso, 2012; Redinger, 2007). 
Adipose tissue also has endocrine functions such as secretion of hormones that work with insulin to 
regulate body fat, and the release of inflammatory adipokines. Due to the increased levels of adipokines in 
adipose tissue, those who are obese are believed to have chronic inflammation, which is associated with 
numerous health problems including metabolic syndrome, diabetes mellitus, hypertension, 
atherosclerosis, some cancers, chronic renal disease and nonalcoholic fatty liver disease (Capurso & 
Capurso, 2012; Kelsey, Zaepfel, Bjornstad, & Nadeau, 2014; Redinger, 2007). 
Metabolic syndrome is a risk factor for type II diabetes mellitus and cardiovascular disease 
(CVD) with multiple signs and symptoms including insulin resistance, increased abdominal fat, high 
triglycerides, high blood pressure, and low levels of high-density lipoprotein cholesterol (HDL-C) 
(“good” cholesterol [American Heart Association, 2015]) (Kelsey at al., 2014). Along with free fatty 
acids, excess abdominal fat leads to increased inflammatory adipokines that contribute to insulin 
resistance by interfering with pancreatic cell function. Dysregulation of lipid and glucose metabolism 
accounts for insulin resistance in type II diabetes mellitus (Redinger, 2007). Adipokines lead to elevated 
macrophage response and infiltration in adipose and other tissue resulting in more inflammation, as well 
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as immune system dysfunction, contributing to metabolic syndrome and other comorbid conditions 
(Redinger, 2007). 
Screening and Detection 
Body Mass Index 
BMI is a common way to measure weight status, as it is convenient and inexpensive, however the 
CDC considers it to be a screening tool for potential health problems, not a diagnostic tool. It is calculated 
the same way for children and adults, but interpreted differently (CDC, 2014). The formula for BMI, 
provided by CDC (2014) is: 
Weight in kilograms / (height in meters)
2
 
Or 
[Weight in pounds / (height in inches)
2
] x 703 
 
Table 4 shows BMI weight status categories for adults. 
 
Table 4. Body Mass Index (BMI) Ranges for Adults 
BMI Weight Status 
<18.5 Underweight 
18.5-24.9 Normal weight 
25.0-29.9 Overweight 
≥30 Obese 
Adapted from the CDC (http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html#Interpreted) 
 
BMI for children and adolescents (defined as those age 20 and younger) is adjusted for age and 
sex because the amount of fat changes with age, and is different for boys and girls. Infants (age 0-36 
months) can be measured using length-for-age percentile, weight-for age percentile, or head 
circumference-for age percentile and weight-for-length percentile. Children and teenagers aged 2-20 are 
measured using stature (height)-for age percentile and weight-for age percentile (CDC, 2014). The 
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calculated number is plotted using a growth chart or data tables (Appendix 1). Youth BMI is reported in 
percentiles (Table 5). 
 
Table 5. Body Mass Index (BMI) Ranges for Children and Teenagers (Ages 0-20) 
BMI Percentile Range Weight Status 
<5
th
 percentile Underweight 
5
th
 to <85
th
 percentile Healthy weight 
85
th
 to <95
th
 percentile Overweight 
≥95th percentile Obese 
Adapted from the CDC (http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html) 
  
Use of BMI to screen weight status is common in the U.S., however some research shows that it 
is not a good indicator of adult adiposity because it measures all body mass, and lean mass, such as 
muscle is not accounted for (Shah & Braverman, 2012; Romero-Corral et al. 2008). Romero-Corral et al. 
(2008) found that in a sample of more than 13,000 adults, the BMI was correlated with both body fat 
percent and lean mass, although lean mass is not body fat. They found that in predicting obesity (BMI 
≥30) had high specificity (96%), but low sensitivity (43%). This shows a low number of obese individuals 
were false positives. However, when based on body-fat percent the BMI missed more than half of the 
people in the study who should have been classified as obese (Romero-Corral et al., 2008). Shah and 
Braverman (2012) also found the same misclassification of obesity when comparing BMI to direct body 
fat measurements in adults. Tools other than BMI to detect obesity include skinfold thickness and waist 
circumference measurement, waist-to-hip-ratio, underwater weighing, bioelectrical impedance analysis 
(using electrical currents to detect body tissue and calculating out water in the body), and dual-energy x-
ray absorptiometry (DXA), which uses x-rays to detect adipose tissue, muscle, and bone mass (CDC, 
2014; Romero-Corral et al. 2008; Shah & Braverman, 2012). BMI is considered to be an accurate and 
acceptable tool for detection of overweight or obesity in children (Waters et al., 2011). 
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Risk Factors for Obesity 
Childhood overweight and obesity are risk factors for being overweight or obese as an adult. 
Furthermore, adults who had been obese as children have a higher risk of developing cardiovascular 
disease and some cancers, even if the weight is lost (Kelsey et al., 2014; Trasande, 2010; Waters et al., 
2011). Risk factors for childhood obesity exist at population, community, and family/individual levels, 
and are often linked to health disparities. Contributing factors to obesity can also fall into environmental, 
genetic, and epigenetic categories (Institute of Medicine [IOM], 2012; Waters et al., 2011; Kelsey et al., 
2014). 
Minority children with lower SES have a higher prevalence of obesity in developed countries, 
however, in developing countries, children in families with high SES have higher rates of obesity. In the 
U.S., this could be explained, in part, by environment: low-income families live in areas that do not have 
safe areas for physical activity such as well-lit parks, walkable sidewalks or trails, or stores that offer 
fresh, healthy food (IOM, 2012; Waters et al., 2011).  Increased sedentary behavior is becoming more 
common in younger generations due to increased technology and “screen time”, which includes watching 
television, playing video games, and increased time on computers, as well as schools eliminating or 
decreasing time for recess or physical education classes. American families also do not eat at home as 
often as they used to, which leads to young people drinking more sugar-sweetened beverages and eating 
more fast food (Barnes, 2010). 
Family and twin studies have shown obesity may be up to 50% genetic. However the 
environment and lifestyle impact genetic factors. The interactions between environmental and genetic 
(epigenetic) factors also play a role in obesity: fetal exposure to tobacco is a risk factor for overweight or 
obesity in childhood (Kelsey et al., 2014, Barnes, 2010). Additionally, women who are obese or have type 
II diabetes are also more likely to have children who become overweight, as the developing fetus is 
subject to the same mechanisms as the mother, specifically, insulin resistance, free fatty acids, and 
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increased inflammation (Kelsey et al., 2014). Gender also influences risk for obesity when puberty 
occurs. It is established in literature that girls develop more adipose tissue and have more distinctive 
patterns of fat distribution than boys. Girls are also less likely to participate in physical activity than boys, 
and that activity is not as beneficial during adolescence to girls as it is to boys (Kelsey et al., 2014; 
Wisniewski & Chernausek, 2009). It is not entirely clear why boys benefit more from physical activity, 
but the hormones insulin and leptin may be associated with lack of energy balance in girls. Girls are more 
likely than boys to have insensitivity to insulin during puberty, which can disrupt regulation of the 
metabolism, however it is unknown whether development of more adipose tissue leads to insulin 
insensitivity or whether insulin insensitivity leads to development of more adipose tissue during puberty 
(Wisniewski & Chernausek, 2009). Leptin is a hormone related to regulation of energy balance and obese 
individuals are insensitive to the hormone. Some studies propose that females may also become 
insensitive to leptin at puberty, which could lead to lack of regulation of energy (Wisniewski & 
Chernausek, 2009). 
Prevalence of Overweight and Obesity  
Worldwide Prevalence 
Overweight and obesity have become prevalent around the world. As of 2014, 39% of adults (age 
≥ 18) were overweight, and 13% were obese. In 2013, 42 million children worldwide under the age of 5 
had a BMI of 85
th
 percentile or higher (overweight or obese) (WHO, 2015).  
United States Prevalence 
Obesity rates in the U.S. are high: 34.9% of adults are obese (BMI ≥30), and 16.9% of youth are 
obese (BMI ≥95th percentile for age/sex). When stratified by race/ethnicity, Ogden and colleagues (2014) 
found that Hispanic youth had highest prevalence of overweight and obesity; 38.9% had a BMI greater 
than or equal to the 85
th
 percentile for age/sex and of those, 22.4% had a BMI greater than or equal to the 
95th percentile.  
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When further stratified for age group and sex, non-Hispanic Asian youth, age 2-5, had the lowest 
prevalence of overweight: 8.3% of males and 9.7% of females had BMIs greater than or equal to the 85
th
 
percentile for age/sex. Non-Hispanic, white females, age 2-5, had the lowest prevalence of obesity (BMI 
≥95th percentile) for all females at 0.6%, and non-Hispanic Asian males, age 2-5, had the lowest 
prevalence of obesity for all males (1.9%) (Ogden et al., 2014). Hispanic youth ages 6-11 had the highest 
prevalence of both overweight and obesity: 48.7% of males and 43.6% of females had BMIs ≥ 85th 
percentile, and of those, 28.6% males and 23.4% females had BMIs ≥ 95th percentile. BMI percentile 
category increased with age in the youth population (Ogden et al., 2014). 
Nevada Prevalence 
 The Nevada Institute for Children’s Research and Policy [NICRP] 2013-2014 Annual 
Kindergarten Health Survey found that children entering kindergarten in Nevada in 2013, aged 4-6, have 
high rates of obesity (BMI ≥95th percentile for age/sex) at 19%. By the 2014 school year this number had 
increased to 21.7% (NICRP, 2015). In 2013, Clark County had the highest rate of obese kindergarteners 
at 20.4% and the rural areas outside Clark and Washoe Counties had the lowest obesity rate (18.4%). 
Among the children sampled, 16.9% were underweight (BMI <5
th
 percentile for age/sex), 49.4% were 
healthy weight (BMI 5
th
 to <85
th
 percentile for age/sex), and 14.7% were overweight (BMI 85
th
 to <95
th
 
percentile for age/sex) (NICRP, 2014). As of 2014, the rural counties had a kindergarten obesity rate of 
23.7%, Clark County was at 21.6% and Washoe County had 20.3% obesity among children aged 4-6. 
Underweight decreased to 16.1%, healthy weight was 52.4%, and 9.8% of children were overweight 
(NICRP, 2015). 
The Data Resource Center for Child and Adolescent Health (DRC), in a partnership with the 
National Center for Health Statistics at the CDC provides the 2011-2012 National Survey of Children’s 
Health (NSCH) results from the random-digit dial survey. The NSCH survey shows that Nevada children 
aged 10-17 have an obesity rate of 18.6%, higher than the national rate of 15.7% for this age group. 
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Nevada children have lower rates of overweight (14.5%) than the national rate (15.6%) for youth age 10-
17 (DRC, 2012). 
Costs of Obesity 
Financial Costs  
Economic analyses of obesity costs have found annual healthcare is more expensive for 
overweight and obese people for those at healthy weight. Studies have found annual healthcare costs for 
overweight and obese youth increase by $172-$220 per child in the U.S. (IOM, 2012; Trasande & Elbel, 
2012). Wang, McPherson, Marsh, Gortmaker, & Brown (2011) state that the increased prevalence of 
obesity combined with the spending on obesity-related costs may account for a 27% increase in U.S. 
health care expenditures from 1987-2001. Additionally, they believe that by 2030, medical costs 
associated with obesity will grow by $48-66 billion/year in the U.S. and by £1.9-2 billion/year in the U.K. 
(Wang et al., 2011).  
Economic models estimate U.S. cost savings as much as $9 billion per year if the prevalence of 
diabetes and hypertension were reduced by 5%, and if other obesity-related comorbid health problems 
were also reduced, savings could be nearly $25 billion. Another model estimated that it would be cost-
effective to spend $2 billion annually in the U.S. on prevention as long as obesity was reduced by 1% in 
12-year-olds because the savings in both childhood and adulthood medical expenditures and quality-
adjusted life-years (QALYs) would be greater (IOM, 2012; Trasande, 2010). 
Quality-of-Life  
The IOM (2012) has found that those who are obese have higher rates of absenteeism from work 
and school than those who are not, and obese people also complete fewer grades in school. Additionally, 
the IOM examined mortality and QALYs, and found a loss of 1-13 years of life per obese person and a 
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loss of 2.93 million QALYs in one year among those who are obese compared with those who are not 
(IOM, 2012).  
 
Asthma and Obesity 
Combined Pathogenesis 
 Members of the American Thoracic Society ad hoc Subcommittee on Obesity and Lung Disease 
have determined that obesity is a risk factor for asthma, and believe that “obese asthma” may be a new 
asthma phenotype. This may be due at least in part to the inflammatory mechanisms, which affect the 
functioning of the immune system in individuals with both obesity and asthma (Dixon et al., 2010). This 
phenotype is believed to be more severe and harder to control than atopic asthma due to physiologic 
differences and altered responses to current medications among obese asthma patients (Black et al., 2013; 
Sutherland, 2014).  
Some research has shown eosinophils are not associated with the obese asthma phenotype, and 
these researchers believe inflammation due to obesity alone can lead to non-allergic asthma through the 
development of T-cells and other mechanisms (Ali & Ulrik, 2013; Jensen, Collins, Gibson, & Wood, 
2011; Jensen, Wood, & Gibson, 2012). Fractional exhaled nitric oxide (FENO) is an indicator of 
eosinophil airway inflammation. In a study examining asthma and BMI, waist circumference and body fat 
percent in children, researchers determined that those who were overweight/obese had low FENO levels, 
showing an association between obesity and non-atopic asthma development (Han, Forno, & Celedón, 
2014). Baumann & Lorentz (2013) found associations between atopic asthma and obesity, but very little 
evidence of allergic mechanisms, such as elevated mast cell numbers, or associations with other allergic 
diseases except atopic dermatitis in children under age 5. Elevated IgE levels were not found in adults, 
and results were inconclusive for children (Baumann & Lorentz, 2013). Studies have also found increased 
Th1 response and decreased Th2 response in obese individuals with asthma. It is hypothesized that there 
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is a Th1/Th2 imbalance due to the chronic, low-grade inflammation from excess adipokines, which 
triggers an innate immune response associated with the Th1 phenotype. Th2 response is associated with 
allergic disease, but not commonly with obese asthma (Ignacio, Kim, & Kim, 2014; Raj, Kabra, & Lodha, 
2014; Rastogi et al., 2014) 
Inflammation signaling cytokines such as tumor necrosis factor-alpha (TNF-α), and markers such 
as high-sensitivity C-reactive protein (hsCRP), and interleukin 6 (IL)-6 are found in higher concentrations 
in obese people than non-obese individuals, and positive associations exist between BMI and hsCRP 
levels, abdominal obesity and IL-6 levels, and adipocyte size and TNF-α levels (Ali & Ulrik, 2013). 
Magrone, Simone, Altamura, & Munno (2014) found inflammatory markers correlated positively with 
elevated BMI in pediatric patients with asthma. 
Obesity is a risk factor for breathing problems in people with and without asthma, however, the 
problems are worse in those with asthma. Along with the pro-inflammatory cytokines and factors secreted 
by adipose tissue, obese individuals have excess pressure on the chest, not from inflammation but from 
extra weight (Dixon et al., 2010). Functional residual capacity (FRC), the amount of air left in the lungs 
after breathing out, is reduced in obese individuals, which is associated with pressure on the lungs, and 
reduction of airway diameter. Airway diameter reduction can also disrupt smooth muscle function and 
lead to airway obstruction (Dixon et al. 2010; Sutherland, 2014). Tidal volume (VT), the volume of air in 
a normal breath, is also decreased in obese asthmatics. While lower VT leads to less strain on the smooth 
muscle in the airway, it can lead to more muscle stiffness, which can lead to stronger contractions and 
increased narrowing of the airways during exacerbations (Ali & Ulrik, 2013; Dixon et al., 2010). 
 
Asthma Severity and Obesity 
 Asthma is more severe in obese individuals. Mechanical factors such as extra weight on the chest 
and reduced airway diameter contribute to the severity of asthma. It has also been suggested that obesity 
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may lead to more frequent inflammatory responses, which trigger exacerbations (Stigone, Ramirez, 
Svensson, & Claudio, 2011; Sutherland, 2014). Those who are overweight or obese also have poorer 
control over asthma, and require more hospitalizations and emergency department visits. Research has 
shown that corticosteroid medication is not as effective for obese adults and children, so they require 
more emergency medication (Black et al., 2013; Forno et al., 2011; Sutherland, 2014). 
Holguin et al., (2011) found the manifestations of comorbid obesity were different between those 
who developed asthma early (<12y) and those who had late onset (≥12y). The obese patients in both 
groups had more severe symptoms, but the patients with early onset asthma had more typical asthma 
symptoms (cough, wheezing, chest tightness), while the late-onset group did not have chest tightness or 
sputum production (Holguin et al., 2011). Holguin and colleagues also found a linear change in BMI 
among early-onset asthma patients, but not in the late onset group. They believe their results suggest 
when one develops asthma earlier in life, the burden of asthma may lead to the development of obesity, 
but when the onset of asthma comes later in life, the obesity leads to a more severe presentation of the 
disease (Holguin et al., 2011). 
 The association between childhood obesity and asthma control and therapy has not been well 
established in the literature. There has been evidence showing inhaled corticosteroids are not effective in 
controlling asthma in obese patients (Baffi, Winnica, & Holguin, 2015; Sutherland, 2014). One study 
found healthy weight asthmatic children had a 44% reduced risk of requiring ED visits and 
hospitalizations after a Childhood Asthma Management Program (CAMP) clinical trial, yet overweight 
and obese children with asthma who were taking the same ICS medication had no reduced risk after the 
trial. Those who were in the healthy weight group also had significantly better lung function with the ICS 
medication, while the overweight and obese children had no significant differences in response to 
medication (Forno et al., 2011). The authors believe since obese patients have more inflammation, which 
they hypothesize has a systemic component, a higher dose of steroids may be required to treat the airway 
inflammation. The higher dose of steroids may also contribute to production of more adipose tissue. Due 
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to this cycle, other medications may be needed for obese asthma patients to gain control of symptoms 
(Forno et al., 2011).  
Weight Loss Interventions for Obese Youth with Asthma 
 Weight loss in pediatric asthma patients has been shown to improve asthma control and lung 
function. Interventions in which children with obesity and asthma lost weight also showed symptom 
improvement, including reduced exercise-induced bronchospasms (EIB) (Abd El-Kader, et al., 2013; van 
Leeuwen, et al., 2014). EIB occurs when airways are obstructed due to exercise, may be indicative of 
poorly controlled asthma, and is likely present in nearly 90% of those who have asthma. Associations 
between obesity and EIB severity have been seen in the literature (Ostrom et al., 2013; van Leeuwen et 
al., 2013). 
 Children and adolescents with asthma have shown lower levels of physical activity (PA) than 
those without asthma. Additionally, asthmatics avoid PA due to asthma symptoms, including EIB, 
interfering with the ability to participate in PA and sports (Abd El-Kader et al., 2013; Ostrom et al. 2013; 
Wanrooij et al., 2014). Research has also shown when parents restrict activity due to symptoms, youth 
with asthma may develop fear of breathlessness (Wanrooij et al, 2014). Results from a questionnaire 
regarding barriers to PA showed that parents saw asthma as a barrier to activity. However, there was no 
statistical difference between activity levels of children with and without asthma, though the asthma was 
self-reported as “well controlled” in this population (Santos-Silva, Melo, Conçalves, Coelho, & Carvalho, 
2014). Social factors may also influence levels of PA. A Norwegian study of adolescents with asthma 
found support from peers and “competence-enjoyment” (wanting to participate in PA) were associated 
with time spent being active (Westergren et al., 2015). 
Wanrooij and colleagues (2014) conducted a systematic review of 29 studies regarding asthma 
and PA. The authors recommended measures for effective interventions, which included individualized 
training intensity levels, and exercise twice at week for 60 minutes each time for at least three months. 
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These recommendations were provided for those with asthma, but not necessarily overweight/obese youth 
to improve overall cardiorespiratory health and EIB (Wanrooij, 2014). 
 Fedele, Janicke, Lim & Abu-Hasan (2014) found that obese asthma patients had lower levels of 
PA than obese non-asthmatics age 7-12 years, though this difference was not statistically significant. Abd 
El-Kader and colleagues (2013) enrolled obese asthmatic 12-18-year-olds in an intervention. The 
treatment group received diet and PA training in addition to medication and the control group only 
received medication to examine inflammatory biomarkers. They found significantly lower levels of TNF-
α, IL-6, IL-8, leptin, and adiponectin in those who received the diet and PA training compared to those 
who did not receive diet and PA training (Abd El-Kader et al., 2013). Cardiovascular fitness has also been 
associated with asthma control and activity. Youth with poorly controlled asthma also had higher levels of 
inactivity and poorer cardiovascular fitness, while those with well-controlled asthma had similar 
outcomes to non-asthmatic children (Vahlkvist, Inman, & Pedersen, 2010). 
 It is known that PA decreases obesity and diseases that are linked to obesity, such as 
cardiovascular disease and type II diabetes, and can be beneficial for mental health as well (Barnes, 2010; 
Kelsey et al., 2014; Wisniewski & Chernausek, 2009). In those with asthma, weight loss can lead to 
increased cardiovascular health and lung function (Dixon et al., 2010; Sutherland, 2014). Gruenfeld, 
Zagarins, Walker, & Skinner (2013) conducted an evaluation of a pediatric exercise intervention called 
the “Fun and Fit Program.” This program targeted children and adolescents who were at risk for obesity 
later in life, similar to the HHP in Southern Nevada. The Fun and Fit Program included PA, nutrition, and 
behavioral health support. The majority of participants were obese at the start of the program (Gruenfeld 
et al. 2013). The authors of this evaluation stated that the program was translated to be a “real world” 
program, and that this approach appeared to be successful.  
This program evaluation did not address asthma specifically, however cardiorespiratory health 
was measured using the Rockport Fitness Walking Test, which estimates maximal oxygen uptake (VO2 
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max) (Gruenfeld et al. 2013). Gruenfeld and colleagues (2013) also examined metabolic equivalents 
(METs) among their population. METs examine the intensity of activity as a ratio of active metabolic rate 
to resting metabolic rate. A MET of 1 is equivalent to the energy expended sitting calmly, while moderate 
activity is equivalent to 3.0 to 6.0 METs , and vigorous activity is >6.0 METs (Heywood & Gibson, 
2014). Gruenfeld et al. (2013) found that the exercise intervention increased the ability for more intense 
activity in their population with a mean change of +1.2 METs (Gruenfed et al., 2013). 
 There are multiple types of tests to estimate VO2 max, which is considered to be the best measure 
of cardiorespiratory fitness. VO2 max can be measured as absolute (liters per minute) and is used in non-
weight-bearing tests such as cycling. Relative VO2 max is measured in milliliters x kilograms per minute 
(mL•kg-1•min-1), and is more commonly used than absolute VO2 max (Heyward & Gibson, 2014). 
Laboratory tests to estimate VO2 max include treadmill, cycle ergometer, recumbent stepper, bench 
stepping, stair climbing, and rowing ergometer tests. Field tests to estimate VO2 max include distance 
running, jogging, or walking tests, and step tests, as well as swimming or cycling tests in some cases 
(Heyward & Gibson, 2014). The Rockport test is a 1-mile walk test, which is optimal for those who may 
not exercise regularly. Klein and colleagues (1987) developed linear regression equations to estimate 
absolute and relative VO2 max. The absolute VO2 max is calculated: 
VO2max = 6.9652 + 0.0091(weight, pounds) – 0.0257(age, years)  
+ 0.5955(sex [male=1, female=0]) – 0.2240(time, min.)  
– 0.0115(heart rate, beats/min.)  
The relative VO2 max (mL•kg-1•min-1), is calculated (Klein et al. 1987): 
VO2max = 132.853 – 0.0769(weight, pounds) – 0.3877(age, years)  
+ 6.1350(sex [male=1, female=0]) – 3.2649(time, min.)  
– 0.1565(heart rate, beats/min.)  
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Heywood and Gibson (2014) provide standard VO2 max values for adults (aged 20 and older) in their 
textbook, and refer readers to the Cooper Institute for Aerobics Research for reference values for children. 
The Cooper Institute has developed a reference guide and testing manual for a physical fitness program 
called FITNESSGRAM®, which is used in the United States for the Presidential Youth Fitness Program 
(Plowman & Meredith, 2013). The Presidential Youth Fitness Program helps train physical educators to 
teach and assess physical activity at schools, improve fitness, empower children to be active, and it 
provides grant funding to assist with these objectives. Partners of the Program include the President’s 
Council on Fitness, Sports and Nutrition, the CDC, the Cooper Institute, the Society of Health and 
Physical Educators: SHAPE America, and the National Foundation on Fitness, Sports & Nutrition 
(Presidential Youth Fitness Program, n.d.).  The Cooper Institute provides reference values for VO2 max 
(mL•kg-1•min-1) for a 1 mile walk test for children aged 5 to >17 using the equation developed by Klein et 
al. (1987). The values are categorized into three fitness levels: Healthy Fitness Zone, Needs Improvement, 
and Needs Improvement – Health Risk (Meredith & Welk, 2013). Table 6, adapted from the 
FITNESSGRAM®/ACTIVITYGRAM® Test administration manual, 4
th
 ed., Meredith & Welk, 2013, 
provides these values. 
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Table 6. VO2 Max Reference Values for Youth Aged 5 to >17 (adapted from Meredith & Welk, 
2013) 
Age Boys Girls 
 Needs 
Improvement 
– Health Risk 
Needs 
Improvement 
Healthy 
Fitness 
Zone 
Needs 
Improvement 
– Health Risk 
Needs 
Improvement 
Healthy 
Fitness 
Zone 
5  
Completion of test. Timing not 
recommended. 
 
Completion of test. Timing not recommended 6 
7 
8 
9 
10 37.3 37.4-40.1 40.2 37.3 37.4-40.1 40.2 
11 37.3 37.4-40.1 40.2 37.3 37.4-40.1 40.2 
12 37.6 37.7-40.2 40.3 37.0 37.1-40.0 40.1 
13 38.6 38.7-41.0 41.1 36.6 36.7-39.6 39.7 
14 39.6 39.7-42.4 42.5 36.3 36.4-39.3 39.4 
15 40.6 40.7-43.5 43.6 36.0 36.1-39.0 39.1 
16 41.0 41.1-44.0 44.1 35.8 35.9-38.8 38.9 
17 41.2 41.3-44.1 44.2 35.7 35.8-38.7 38.8 
>17 41.2 41.3-44.2 44.3 35.3 35.4-38.5 38.6 
Adapted from: FITNESSGRAM®/ACTIVITYGRAM® Test administration manual, 4
th
 ed., Meredith & Welk, 
2013, pgs 65-66 
 
 
 VO2 max values for overweight and obese children have been found to be lower than for healthy-
weight children (Farpour-Lambert et al., 2009; Melo et al., 2015; Silva et al., 2014), and inversely 
correlate with BMI, BMI z-score, body fat percentage, and waist circumference (Starkoff, Eneli, Bonny, 
Hoffman & Devor, 2013). In two studies, mean VO2 max values for obese children and adolescents were 
as low as 19.7 SD±6.0 (Starkoff et al., 2013) and 27.7±4.17 Silva et al. (2014), considerably lower than 
the lowest standard FITNESSGRAM® values reported in Table 6. Melo and colleagues (2015) found that 
children with a “high” waist circumference, defined as ≥85th percentile had a mean VO2 max of 
31.82±5.18, which was significantly lower than both those with “middle” waist circumference (>50th to 
<85
th
 percentile) who had a value of 39.14±6.49, and those with low waist circumference (50th 
percentile) who had a VO2 max value of 46.68±7.03 (Melo et al., 2015). 
 Ernesti and colleagues (2013) found that among children with asthma, those who are overweight 
or obese also have significantly lower VO2 max than those who are healthy weight. Those with obesity 
40 
 
and asthma had a VO2 max of 38.3±5 and those who were overweight had a VO2 max of 40.6±8.7, while 
children with asthma who were classified as healthy weight had a VO2 max of 43±8.6 (Ernesti et al., 
2013). Shim and colleagues (2013) found obese asthmatic adolescents (21.7±4.5) and obese non-
asthmatic adolescents (21.4±5.4) both had significantly lower values than healthy weight, non-asthmatic 
controls (35.3±5.8)  (Shim et al., 2013). 
 Many controlled exercise and/or nutrition interventions have been created for youth with obesity 
and asthma. While Gruenfed and colleagues (2013) have provided a promising evaluation of an exercise 
program for youth at risk for obesity in adulthood, there is still a gap in the literature as to whether such 
an intervention program could be beneficial to children who are obese and have asthma. This paper will 
evaluate an existing exercise program targeted at children who are at risk for adult obesity (the Healthy 
Hearts Program), and assess the feasibility of such a program for children with asthma, and if feasible, the 
benefit compared to youth without asthma. 
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CHAPTER 3. METHODOLOGY 
Study Design 
 This research is a retrospective analysis of two Nevada populations, one from Reno, NV, and the 
other mainly from the Las Vegas area. The first dataset, from Reno, yielded a cross-sectional analysis 
examining the association between asthma and weight status. The Reno pilot data were collected from 
pediatric medical records at the UNSOM Pediatric Allergy/Immunology Clinic.  
 The second dataset was obtained from the main office of the Children’s Heart Center Nevada 
(CHC) in Las Vegas. The data from CHC were obtained retrospectively from medical records of 
overweight and obese youth with and without asthma who were enrolled in the HHP. The CHC data were 
collected for routine CHC medical records and for HHP intervention purposes.  
Data Collection and Study Populations 
UNSOM Reno Pilot Study Data 
 The data for this study were obtained from medical records and new patient intake forms from 
patients at the UNSOM Pediatric Allergy/Immunology Clinic. Patients with asthma who had been seen by 
a pediatric allergy physician, and who had skin prick tests for IgE sensitization to Northern Nevada 
allergens performed between June 1, 2009 and June 1, 2012 were recruited for a final sample size of 101. 
Of these 101 children, 98 had complete BMI data, and were included in this study. The data for this 
portion of the study were de-identified before being uploaded to a password protected electronic database.  
Twenty-seven additional subjects were able to be added to the dataset, from a concurrent allergy study 
(Great Basin Mold project), as both studies fell under  the same Institutional Review Board (IRB) 
protocols. Only asthmatic patients in the Great Basin Mold study were eligible to be combined with the 
original asthmatic population. One of the conditions of the IRB required the de-identification of patients, 
which had already been performed prior to receiving the data. Another requirement from the funding 
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agency, the Nell J. Redfield Foundation, for combining populations was that the patients had skin prick 
test results performed for the Northern Nevada allergens mentioned above, with clinical results reported. 
Both populations met these criteria, and asthmatic patients from the Great Basin Mold study were 
combined with the original asthmatic population. The population is comprised of patients under age 18. 
Additionally, appropriate statistical tests, including Pearson chi-square, Fisher exact tests, 
Wilcoxon W, and independent sample t-tests (depending on distribution and sample sizes within groups) 
were performed to determine whether or not the groups were demographically and clinically similar 
enough to be combined. Analyses between the two populations indicated that they were similar enough to 
be combined for analyses purposes (Table 7). 
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Table 7. Population Differences between Eligible Reno Study Participants (N=125) 
 Variable Asthma Study 
(N=98) 
Mold Study 
(N=27) 
Test-statistic & 
value 
p-value 
Sex 
   Male  
   Female 
 
n=61 
n=37 
 
n=15 
n=12 
 
Pearson chi-
square=0.379 
 
0.582 
Insurance Status 
  Private Insurance 
  Other Insurance 
 
n=73 
n=24 
 
n=20 
n=7 
 
Pearson chi-
square=0.016 
 
0.900 
Race/Ethnicity 
  White 
  Hispanic/Latino 
  Other 
 
n=58 
n=27 
n=13 
 
n=23 
n=3 
n=1 
 
Fisher’s exact 
test=0.003 
 
0.046 
Asthma Severity  
  Mild 
  Moderate 
  Severe 
  (Mild) Intermittent 
 
n=7 
n=66 
n=17 
n=7 
 
n=1 
n=16 
n=6 
n=4 
 
Fisher’s exact 
test=0.008 
 
0.512 
Atopy (Y/N) 
  Positive 
  Negative 
 
n=77 
n=19 
 
n=25 
n=2 
 
Fisher’s exact 
test=0.080 
 
0.158 
BMI Category 
(CDC) 
  Under/healthy wt 
  Overweight 
  Obese 
 
n=61 
n=18 
n=12 
 
n=21 
n=4 
n=2 
 
Fisher’s exact 
test=0.038 
 
0.656 
BMI Percentiles 
  0-25% 
  26-50% 
  51-75% 
  ≥76% 
 
n=14 
n=13 
n=22 
n=41 
 
n=5 
n=6 
n=6 
n=9 
 
Fisher’s exact 
test=0.0053 
 
0.611 
Atopy (# +allergens) n=96, 
median=15.50, 
range (0,56) 
n=27, 
median=9.00, 
range(0, 23) 
Wilcoxon 
W=1398.5 
0.091 
Age (years) n=98, 
median=6.00, 
range (1,15) 
n=27, 
median=10.00, 
range (3,16) 
Wilcoxon 
W=2196.0 
0.003 
FEV1% n=70, µ=97.37, 
SD(14.17) 
n=22, µ =95.41, 
SD(10.90) 
t= -0.92 0.359 
FEV1/FVC n=70, µ =95.11, 
SD(8.68) 
n=22, µ =96.32, 
SD(8.62) 
t= -0.57 0.571 
FEF25-75 n=70, µ =78.99, 
SD(20.90) 
n=22, µ =82.68, 
SD(18.23) 
t= -0.74 0.459 
Abbreviations: SD standard deviation, µ mean 
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Reno Pilot Study Variables 
The pilot study database included 66 original variables such as demographics: age, insurance status, sex, 
race/ethnicity; Obesity status: BMI percentile (calculated for age/sex per CDC standards using height and 
weight data collected at the initial clinic visit). BMI percentile had been collapsed into categories before 
de-identification occurred, and therefore, could only be used as a categorical variable. Individual height 
and weight data were not included in the de-identified dataset per the IRB.  
Also included were clinical variables: signs and symptoms during physical examination, pulmonary 
function tests (spirometry measures), asthma severity as diagnosed by physician (one doctor at the Reno 
clinic assessed asthma severity for all patients); Medical history: history of respiratory syncytial virus, 
exacerbating factors, food and drug allergies, surgical history, and environmental triggers (animal 
exposure, smoking near child, bedding, heating and cooling in the home, type of home); and control 
measures, all measured from the previous year before visit/referral to an allergist: number of courses of 
oral steroids used in the past year before seeing the doctor at the Reno clinic, number of visits to the 
emergency department (ED) in the past year due to asthma, number of overnight hospitalizations in the 
past year due to asthma, number of missed school days in the past year due to asthma, and asthma 
medications/dose at first visit and after adjustment by a pediatric allergy physician. 
Some variables had missing data and could not be used in this study. Additionally, skin prick tests 
results for IgE sensitization to numerous types of molds, weeds, inhalants, grass, trees, and animals were 
included in the dataset (Hogan et al. 2016) (Appendix 2).  The cleaned, recoded data was transferred to 
IBM
®
 SPSS
®
 Statistics, versions 22 and 23 for the majority of analyses. All patients were assessed at the 
first visit in order to obtain baseline measures of asthma severity and control. 
Reno Pilot Study Ethical Considerations 
 This protocol received an exemption from the IRB for the Office of Human Research Protection 
at University of Nevada, Reno (UNR) (Protocol #E12-074), approved 6/26/2012. Also approved were a 
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waiver of informed consent, and a HIPAA waiver for the use of medical records. An agreement for 
University of Nevada, Las Vegas (UNLV) intent to rely on the UNR IRB was finalized on 5/17/2013. All 
data were de-identified by clinic staff before any analyses occurred. 
Healthy Hearts Program Background and Data 
 Data from two electronic health record (EHR) databases at CHC were collected to create a dataset 
of asthma patients, and control patients without asthma who participated in the 12-week HHP nutrition 
and exercise intervention for overweight and obese children. Much of the data came from the HHP intake 
form located in each patient’s record. A copy of the intake form is located in Appendix 3. 
 The family-based HHP was created in 2002 with the goal of promoting healthy lifestyles by using 
behavior modification such as improving diet, physical activity levels, and self-esteem for overweight and 
obese children, and those otherwise at risk for heart disease. This behavior modification helps to reduce 
the risk of chronic diseases such as type II diabetes, hypertension, heart disease, and other comorbid 
disorders (CHC, 2015). CHC patients are referred to the HHP for the following reasons: 
 Overweight (>85th percentile for age)  
 High cholesterol (>170 mg/dL) 
 Family history of premature heart disease (“first degree male relative before the age of 55 or a 
female relative before the age of 65”) 
 Have a parent with high cholesterol (>240 mg/dL) 
 Have risk factors for heart disease, which include: obesity, hypertension, diabetes, 
hyperinsulinemia (high insulin levels), or hyperlipidemia (high lipid levels) (CHC, 2015).  
The first step of the program is an evaluation with a cardiologist and an electrocardiogram (EKG) test to 
examine cardiac function. The next step is consultation with a dietician, after which the 12-week fitness 
and nutrition activities begin. At weeks 1, 6, and 12, height, weight, percent body fat, waist 
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circumference, and blood pressure are measured (Figure 3). Patients may continue to follow up with 
dieticians every three months, and they may repeat the program multiple times, and into adulthood if they 
choose. The goal for those entering the program with with a BMI between the 85
th
-96
th
 percentiles is 
weight maintenance as long as there are no other risk factors for heart disease. The protocol is follow-up 
counseling every three months and laboratory tests every six months. The goal for those entering with 
with a BMI percentile ≥97th is weight loss, and the protocol for these patients is follow-up counseling and 
laboratory tests every three months (CHC, 2015). Cardiac rehabilitation is also offered to patients with 
cardiac diagnoses. The rehabilitation includes exercise tolerance improvement and education about heart 
disease (CHC, 2015). The program is conducted in both English and Spanish. 
 
 
Figure 3. Healthy Hearts Program Procedure (adapted from HHP literature) 
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In this study, two groups of patients were compared:  
1) Pediatric overweight or obese patients who were in the program and had asthma 
2) A control group of pediatric overweight or obese patients who were in the program and who did 
not have asthma.  
For this study, overweight/obese children had a BMI of 90
th
 percentile or higher at the beginning of the 
intervention, as instructed by the CHC Director of Research. Asthma was defined as having a diagnosis of 
asthma, a diagnosis of reactive airway disease (RAD) and/or prescribed one or more medications for 
asthma control. Medical record searches included brand name and generic medications (Table 8). 
 
Table 8. Asthma Medications taken by the Healthy Hearts Program Population 
Type Generic Name Brand name(s) 
Inhaled Corticosteroids (ICS) Beclomethasone QVAR
®
 
 Budesonide  Pulmicort
®
 
 Fluticasone propionate Flovent
®
 HFA, Flovent
®
 
Diskus
®
 
 Mometasone Asmanex
®
 
   
ICS in combination with 
long-  
Budesonide/formoterol Symbicort
®
 
acting -agonists (LABAs) Fluticasone/salmeterol Advair
®
 
 mometasone/formoterol Dulera
®
 
   
Emergency Medications   
   Short acting -agonists Albuterol, Albuterol Sulfate ProAir
®
, Ventolin
®
 
 Levalbuterol HCl Xopenex
®
 
   
   Anticholinergics (AC) Ipratropium bromide Atrovent
®
 
 Titropium bromide  Spiriva HandiHaler
®
 
   
   Combined SABA/AC Ipratropium bromide/ 
albuterol sulfate 
DuoNeb
®
 
   
Leukotriene Modifiers Montelukast Singulair
®
* 
* Singulair included if in combination with another medication on the list, as this drug is also taken for  
allergies alone 
 
In total, 86 children with asthma and 146 youth without asthma met inclusion criteria. Inclusion 
criteria were: male and female patients, age 5-18 years who participated in the HHP from 2004 to 
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December 2014. Exclusion criteria include records from patients with congenital heart disease, 
developmental delay, or other medical inability to do the exercise program (for reasons other than 
asthma). Data were de-identified before analyses were conducted. The majority of children who did the 
intervention program did so in Las Vegas, however a small number of participants lived in Reno, where 
the intervention program also took place prior to 2010. 
CHC Study Variables 
Pre and post intervention variables included in the dataset were:  
 BMI percentile and z-score  
 Metabolic equivalents (METs) for intensity of activity 
 Maximal oxygen consumption (VO2max)  
 Laboratory test results (total cholesterol, HDL/LDL, triglycerides, insulin, C-reactive protein 
[CRP])  
 Vital signs: blood pressure (mmHg) and heart rate (beats/minute)
 HHP protocol specifies to only repeat laboratory tests if the pre-tests are abnormal, therefore 
many patients did not have post-test laboratory results. Additionally, if a child quit the program before 
completion (attrition), other post-test variables were not available.  
Other variables included sociodemographic variables: age in years, race/ethnicity (collapsed to 
Hispanic and non-Hispanic due to a high proportion of Hispanic children in the program [>60%]), sex 
(m/f), and insurance status (insured, uninsured, or Medicaid recipient – uninsured and Medicaid 
categories were combined for analysis due to the small sample of uninsured patients [n=10]); Asthma 
status (y/n) and medications for asthma/RAD (listed above in Table 7); Other medications, comorbid 
diagnoses, and allergies. 
Also included were program completion variables: Start/end date of program, whether or not the 
child finished the program in 12 weeks, how many weeks the child showed up for the program, if the 
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program was done one time or more (first time in program was used for consistency and reduction of 
bias), how the visit was coded in the EHR (completed or not completed), and whether the staff coded the 
program as completed. 
If a child missed a week during the program, but showed up the next week, the visits could be 
combined, for example if the child missed week 3 but showed up week 4 and completed all requirements, 
the visit could be coded as “week 3/4” and was regarded as two visits. For this reason, not all children 
who “completed” the program used the full 12 visits. Many patients completed the program by week 10, 
and some finished as early as weeks 6-9. The HHP staff determined whether the child met the 
requirements to be considered “completed”, which is the time variable used in this study as “time in 
program,” as a dichotomous variable for event in Cox proportional hazards regression, while “weeks in 
the program” is used continuously in other analyses. This measure was selected because I believe the staff 
working with the children and families on a regular basis are more likely than an EHR system to know 
whether or not the child has completed the requirements of the program. 
Healthy Hearts Program Ethical Considerations 
The IRB for the Sunrise Health Office of Research Compliance conducted a full review and 
approved the protocol for this study (Protocol # 14-025), approved 11/5/2014. A waiver of informed 
consent was also approved. An exemption was received from the IRB at the Office of Research Integrity 
– Human Subjects at UNLV, due to the use of de-identified data, and because the protocol had already 
been reviewed and approved by the Sunrise Health IRB (UNLV protocol #1412-5020M), approved 
12/5/2014. All data were de-identified by the office of the Director of Research at the Children’s Heart 
Center prior to analyses. 
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Research Questions and Hypotheses 
The overall objective of this study was to examine the associations between pediatric 
asthma/allergy and obesity status in Nevada, and to determine whether or not a feasible intervention exists 
to help asthmatic youth with elevated BMI lose weight. 
Question 1: Is elevated BMI associated with asthma severity within a select group of children with 
asthma from a Reno UNSOM pediatric allergy/immunology clinic? 
Ho: There will be no difference among asthma severity by BMI percentile category 
Ha1: Those with an elevated BMI (overweight or obese percentile groups) will have more severe 
asthma than those with a healthy BMI by doctor diagnosed severity 
Ha2: Those with an elevated BMI (overweight or obese percentile groups) will have more severe 
asthma than those with a healthy BMI by pulmonary function tests 
Ha3: Those with an elevated BMI (overweight or obese percentile groups) will have more severe 
asthma than those with a healthy BMI by proxies of severity, such as financial cost and 
quality-of-life measures 
Question 2: Within the Reno pediatric pilot population is elevated BMI associated with allergen 
sensitization or asthma/allergy triggers? 
Ho: There will be no difference among the number/type of allergies or the number of 
asthma/allergy triggers by BMI percentile  
Ha1: There will be a difference in allergen sensitization as evidenced by positive skin prick tests, 
among those with elevated BMI and those in the healthy BMI category 
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Question 3: Will the 12-week physical activity intervention be feasible for overweight/obese children 
with asthma compared to overweight/obese children without asthma among the CHC population (due to 
those with asthma being prone to respiratory distress when exercising)? 
Ho: There will be no difference between asthmatic and non-asthmatic children with elevated BMI 
in completion of the program 
Ha1: There will be a difference in completion rate between asthmatics compared to non-
asthmatics with elevated BMI 
Analysis of data 
 Data were analyzed using SAS
®
 version 9.4, IBM
®
 SPSS
®
 Statistics, version 22 and 23, and 
Microsoft
®
 Excel
®
 for Mac 2011 and Microsoft
®
 Excel
®
 2010 for PC. Komolgorov-Smirnov and Shapiro-
Wilk tests, as well as visual examination of histograms with normal curves were used to determine 
whether the use of parametric or non-parametric tests were appropriate (Pallant 2013).  Descriptive 
statistics were performed separately for each population on both quantitative and re-coded qualitative 
(nominal and non-numeric categorical) variables to obtain frequencies and measures of central tendency 
to summarize each population’s characteristics. Additionally, paired t-tests (or Wilcoxon Signed Ranks 
tests) were performed to examine crude pre-post differences in BMI percentile, BMI z-score, VO2max, 
METs, heart rate, and blood pressure among CHC populations with and without asthma pre-and post-
intervention (Field, 2013). Independent sample t-tests or Mann-Whitney U tests were performed to test 
differences between those with and without asthma at baseline and after intervention (Field, 2013). 
Reno Pilot Study 
Research Question 1, Hypothesis 1 
The first research question examines association between elevated BMI and asthma severity. To 
test the first alternative hypothesis, that asthma will be more severe in those with an elevated BMI 
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(overweight or obese percentile group) compared to those with healthy BMI, crude and adjusted 
multinomial logistic regressions were conducted (Field, 2013).  
Asthma severity was the dependent variable. Mild and intermittent asthma were combined for 
adequate sample size giving the dependent variable three categories: mild/intermittent, moderate, and 
severe asthma. The independent variable was BMI percentile category (underweight/healthy weight, 
overweight, and obese). The underweight patients were combined with healthy weight patients due to the 
small sample size of the underweight group (n=4). The adjusted regression model also included age in 
years, race, and sex (m/f). The race/ethnicity variable was dichotomized (white and “other race”). “Other 
race” includes Hispanic/Latino youth (24%), and less than 5% each of Asian, black, Hawaiian Islander, 
Native American, multiracial, and “other race” patients. Pearson and Deviance goodness-of-fit tests were 
conducted (Field, 2013). 
Research Question 1, Hypothesis 2 
The second alternative hypothesis from Question 1, that those with elevated BMI will have more 
severe asthma based on pulmonary function was tested using one-way analyses of variance (ANOVAs). 
Measures of lung function are the continuous dependent variables. Spirometry measures (FEV1%, 
FEV1/FVC%, and FEF25-75%) are continuous variables. BMI percentile is the independent variable 
(1=underweight, 2=healthy weight, 3=overweight/obese). The Levene test for homogeneity of variance 
was conducted for each measure (Field, 2013).  
Research Question 1, Hypothesis 3 
The third alternative hypothesis for Question 1 examines elevated BMI in relation to proxies for 
asthma severity. These proxies for asthma severity include:  
 Number of courses of oral steroids used in the past year for asthma  
 Number of hospitalizations in the past year due to asthma  
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 Number of ED visits in the past year due to asthma  
 Number of missed school days in the past year due to asthma  
All proxy measures for asthma severity were dichotomized due to positive skew and a large 
proportion of zero values. Chi-square tests were conducted to examine the associations between BMI 
percentile and the proxy measures. Two of the proxy variables (hospitalizations and missed school days) 
had more than 20% of cells with expected counts lower than 5, therefore chi-square tests were not 
appropriate (Pallant, 2013). Fisher exact tests were subsequently conducted on the hospitalization and 
missed school day variables to examine the associations between the variable and BMI percentile 
category. The only significantly associated variable, oral steroid use, was then used in crude and adjusted 
binary logistic regression as the dependent variable. BMI percentile category was the independent 
variable and the regression was adjusted for age in years, sex (m/f) and race (dichotomized, as stated 
above in Question 1, hypothesis 1). The Hosmer and Lemeshow goodness of fit test was used to examine 
model fit (Pallant, 2013). 
Research Question 2 
The hypothesis for the second research question regarding allergic sensitization associations to 
elevated BMI percentile, was tested using two separate multiple logistic regressions. The dependent 
variable for the first regression was atopy (allergen sensitization) (positive/not positive) and for the 
second regression polysensitization (y/n). For both regressions BMI percentile was the independent 
variable. The models were also adjusted for age in years, sex (m/f), and race (white and other race as 
defined above). 
Skin prick test results for IgE sensitization to eight types of molds, 10 types of weeds, 10 types of 
indoor inhalants, six types of grass, 20 types of trees, and nine types of both household and non-
household animals specific to Northern Nevada are included in the in the dataset (Hogan et al. 2016) 
(Appendix 2). Positive skin prick test results to the allergens were summed to create a continuous 
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variable. A number between 0 and 63 was assigned to each patient, in which 0=no allergic reactions and 
63=allergic to every aeroallergen tested. Atopic patients are sensitized to at least one allergen. 
Polysensitized patients are sensitized to two or more allergens (Migueres et al. 2014). Kolmogorov-
Smirnov tests and histogram examinations demonstrated non-normal distribution of atopy score. 
Polysentitization was a dichotomous variable (y/n). 
Transformations were attempted to normalize the variable and included square root 
transformation, log(1+y) transformation (y=random variable), inverse transformation (1/[y + 1]), Box-
Cox transformation (van Belle, Fisher, Heagerty, & Lumley, 2004) , and a two-step procedure to 
normalize data as described by Templeton (2011) which includes ranking cases and applying inverse 
normal distribution function to the ranked values to produce z-scores of the values (Templeton, 2011). No 
method produced a normally distributed atopy variable; atopy was dichotomized to use in logistic 
regression. Hosmer and Lemeshow goodness of fit tests were used to assess model fit for each regression 
model (Pallant, 2013). 
Children’s Heart Center Study 
Research Question 3 
 The hypothesis to test the third research question, that there will be a difference in outcomes 
between overweight/obese children with and without asthma in the HHP intervention, Cox Proportional 
Hazards regression was utilized to examine attrition rates and repeated measures ANOVAs to examine 
outcome measures in the patients who finished the intervention. Adjusted models included age in years, 
race/ethnicity (Hispanic/non/Hispanic), sex (m/f), and insurance status (Insured/Medicaid recipient).  As 
noted above Medicaid recipients and uninsured patients were combined due to the small number of 
uninsured patients (n=10, 4.3% of the population). The race variable was dichotomized because the 
proportion of patients who reported “Hispanic” as their race was 64.2% (n=149). The non-Hispanic group 
is comprised of 12.1% black children (n=28), 16.8% white children (n=39), 2.6% Asian children (n=6), 
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1.3% American Indian/Alaska Native (n=3), 1.3% who reported “other race” (n=3) and 1.7% with no 
reported race (n=4). Number of comorbid diagnoses was also added as a covariate to all multivariable 
analyses, but it did not end up in any final models as it was not significant. 
 Proportional hazards assumptions were tested on independent variables (asthma [y/n], 
race/ethnicity (Hispanic/not Hispanic), sex (m/f), insurance status (insured/Medicaid). Age is continuous, 
but the ages only range from 6-18. To determine whether the covariates violated the proportional hazards 
assumption, each variable was examined by computing a time dependent covariate in SPSS 
(T_*variable). Log minus log plots were examined as well (Hosmer, Lemeshow, & May, 2008).  
In the Cox regression, the time variable was time in weeks in the program, the event was defined 
as “finished the program” (“1”), based upon the coding provided by the CHC staff as discussed 
previously in the CHC Variables section. Asthma status (y/n) was the independent variable, with age, 
race/ethnicity, and sex as covariates in the adjusted model.  
Two main outcome measures from the program will be examined in this study to assess the 
difference between asthmatic and non-asthmatic patients. These measures are BMI z-score, which was 
selected because the objective of the program is to maintain or lose weight for heart health, and VO2 max. 
Oxygen consumption was examined because youth with asthma, especially those who are overweight or 
obese, have difficulty during physical activity due to exercise-induced bronchospasm (Ostrom et al., 
2013; van Leeuwen et al., 2013). Asthma status (y/n) is the dichotomous predictor variable, and time in 
weeks is included in each model. Time for BMI z-score has three measures (weeks 1, 6, and 12), and 
VO2 max has two measures (weeks 1 and 12). The CHC staff uses the Rockport 1-mile walk test to 
calculate relative VO2 max (mL/Kg/min) using Klein et al.’s (1987) equation (Klein et al., 1987). 
Repeated-measures ANOVAs were conducted on the two outcome measures from the program: 
BMI z-score and VO2max to determine whether the outcomes were different between children with and 
without asthma. Covariates were added to create repeated-measures analysis of covariance (ANCOVA) 
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models. The covariates included: race/ethnicity (Hispanic/not Hispanic), sex (m/f, for the BMI z-score 
model), insurance status (insured/Medicaid), and age (continuous). Two separate analyses were conducted 
to examine pre-post difference in VO2max, one for boys and one for girls. As seen in Table 6 in the 
literature review, VO2max reference values increase overall as health increases, yet the values also 
increase as age increases for boys, but decrease as age increases for girls (Meredith & Welk, 2013). A 
combined sex model was not appropriate hence stratification was performed.   
Power analyses, using G*Power version 3.1.9.2, were conducted to determine adequate sample 
size. Effect size to calculate sample size was estimated (Lakens, 2013; Sullivan & Feinn, 2012) by using 
effect sizes from three meta-analyses in which interventions to reduce obesity in pediatric populations 
were examined (Janike et al., 2014; Kitzmann et al., 2010; Yavuz, van Ijzendoorn, Mesman, & van der 
Vook, 2015). The average effect size from a combined 136 studies was 0.321. Using this estimate to 
determine sample size for repeated measures ANOVA models using the F-statistic, for BMI z-score, a 
sample size of 24 patients overall was required for a power of 80%, and a sample of 38 children overall 
was required for a power of 95%. For VO2max, a sample of 22 children was required for a power of 80%, 
and a sample of 34 children was required for a power of 95%.  
While BMI percentiles for children are adjusted for age and sex, they are not comparable among 
children of different ages or between males and females. Z-scores are comparable measures, which are 
defined by the number of standard deviations from a mean value (Wang & Chen, 2012). For example, if 
one were to look at the last BMI growth chart in Appendix I (Page 93) BMI for Age for girls, they could 
see that a BMI of 18 would put a 4-year-old girl at the 95
th
 percentile, yet a 15-year-old girl would have a 
BMI slightly below the 25
th
 percentile. While it is not necessary for clinicians to compare these two girls, 
by assigning a standardized value these girls can be compared using statistical software that can adjust for 
age as a number, but not for puberty or hormonal differences which alter body mass with age, as noted in 
the literature review.  
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BMI percentile is a rank, while the z-score is a continuous value between -3 and +3. In a normal 
distribution, -3 corresponds with a BMI percentile of 0.2
nd
, -1.96 is the 2.5
th
 percentile, 0 is the 50
th
 
percentile, +1 is the 84
th
 percentile, +1.96 is the 97.5
th
 percentile, and +3 is 99.8
th
 percentile, as would be 
expected in a normal curve (Wang and Chen, 2012). The equation for a z-score is: 
     Z = (x - )/ 
Where x=individual value, =population mean (such as the national mean, which is an external measure 
needed to standardize the value [Must & Anderson, 2006]), and =standard deviation of the population 
(Wang and Chen, 2012).  
The CDC provides a SAS program to calculate BMI z-scores (CDC, 2016a). Calculation using 
the SAS program includes the use of potentially identifiable variables (such as date of birth) meaning the 
calculation needed to be conducted at the CHC. The available CHC computers do not have SAS installed, 
therefore, an online calculator from the Children’s Hospital of Philadelphia (CHOP) Research Institute 
was used to calculate z-scores for patients who did not have a calculated z-score and to double check 
those who did have a z-score in the medical records to avoid bias from rounding numbers at two decimal 
places. The CHOP Research Institute’s program uses calculations based on CDC growth charts adjusted 
for age and sex (CHOP Research Institute, 2016); the CHC uses the same calculation. 
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CHAPTER 4. RESULTS 
Reno Population – Demographics & Descriptive Characteristics  
Table 9 shows demographic characteristics and BMI percentile categories for the Reno 
population (N=125). The population was comprised of youth aged 1-16 (median age: 7 years), of whom 
60.8% (n=76) were male, 39.2% (n=49) were female, 64.8% (n=81) were white, and 24.8% (n=31) were 
of another race and/or ethnicity.  Seventy-four percent (n=93) of these children had private medical 
insurance, while 24.8% (n=31) had another form of health insurance (other includes Medicaid, no 
insurance, tribal insurance, self-pay, or multiple forms of insurance); one case was missing insurance 
data. Eighty-two children (65.6%) were in the under/healthy weight BMI category (<85
th
 percentile), 22 
(17.6%) were classified as overweight, and 14 children (11.2%) were in the obese category (Table 9). 
 
Table 9. Population Characteristics of Reno Patients (N=125) 
 Variable N(%) 
Sex  
   Male 76 (60.8) 
   Female 49 (39.2) 
Insurance Status  
  Private Insurance 93 (74.4) 
  Other Insurance 31 (24.8)* 
Race/Ethnicity  
  White 81 (64.8) 
  Other 44 (35.2) 
BMI Percentile Category  
   Under/healthy weight (<85
th
 percentile) 82 (65.6) 
   Overweight (85
th
 to <95
th
 percentile) 22 (17.6) 
   Obese (≥95th percentile) 14 (11.2)* 
 Median (range) 
Age (years) 7.00 (1-16) 
*Insurance status, 1 missing case; BMI percentile category, 7 missing cases 
 
Asthma and allergy related characteristics of the Reno population (N=125) are shown in Table 
10. Asthma symptom severity was moderate in 82 cases (66%) and severe in 23 cases (18%), and severity 
was missing for one case. Atopy occurred in 82% of children (n=102), pollen atopy (sensitization to 
grass, weeds, and trees specifically) occurred in 74% (n=93) of the population, and 79% were 
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polysensitized (n=99). The children in this population were sensitized to a median of 11 allergens, and a 
median of 7.5 pollen allergens (Table 10). The number of courses of oral steroids required for asthma 
control in the past year ranged from 0-6; 38.4% (n=48) of patients required one or more courses of oral 
steroids in the past year due to asthma. Four percent (n=5) of the population missed 1 or more days of 
school in the past year due to asthma, 24.8% (n=31) required 1 or more ED visits, and 7.2% (n=9) 
required 1 or more overnight hospitalizations in the past year due to asthma. Cases missing data are also 
reported in Table 10. 
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Table 10. Asthma/allergy Characteristics of Reno Patients (N=125) 
 Variable N(%) 
Asthma Severity  
  Mild/Intermittent 19 (15.2) 
  Moderate 82 (65.6) 
  Severe 23 (18.4) 
  Total* 124 (99.2)* 
Atopy (Y/N)  
  Positive 102 (81.6) 
  Negative 21 (16.8) 
  Total* 123 (98.4)* 
Pollen Atopy (Y/N)  
  Positive 93 (74.4) 
  Negative 21 (16.8) 
  Total* 114 (91.2) 
Polysensitized (Y/N)  
   Yes (≥2 allergens+) 99 (79.2) 
   No (0-1 allergens+) 24 (19.2) 
  Total* 123 (98.4)* 
Number of courses of oral steroids in past year (range=0-6)  
   0 77 (61.6) 
   1 or more 48 (38.4) 
  Total 125 (100) 
Number of school days missed in past year (range=0-23)  
  0 120 (96) 
  1 or more 5 (4) 
  Total 125 (100) 
Number of emergency department visits in past year 
(range=0-9) 
 
   0 94 (75.2) 
   1 or more 31 (24.8) 
  Total 125 (100) 
Number of overnight hospitalizations in past year (range=0-2)  
  0 116 (92.8) 
  1 or more 9 (7.2) 
  Total 125 (100) 
 Median (Range) 
Atopy score (# +allergens)* 11 (0-56) 
Pollen atopy (# + allergens)* 7.5 (0-36) 
 Mean (SD) 
FEV1% predicted* 93.10 (13.49) 
FEV1%/FVC* 95.40 (8.64) 
FEF25%-75%* 79.87 (2.12) 
*Asthma severity, 1 missing case (0.8% of population);  Atopy (Y/N), 2 missing cases (1.6%);   
Pollen atopy (Y/N), 11 missing cases (8.8%); Polysensitized Y/N, 2 missing cases (1.6%),  
Atopy(#), 2 missing cases (1.6%); Pollen atopy (#), 11 missing cases (8.8%), all PFTs, 33 missing cases 
 
 
 A breakdown of asthma severity by BMI status is shown in Table 11. Of those who are 
overweight, 1.7% had mild or intermittent asthma, and of those who are obese, 1.7% had mild or 
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intermittent asthma. Seven obese children (5.9%) had moderate asthma, and 17 overweight youth (14.4%) 
had moderate asthma. Three overweight children (2.5%) had severe asthma, and five obese children 
(4.2%) had severe asthma (Table 11). 
 
Table 11. Reno Pilot Population Asthma Severity by BMI Status (N=118) 
 Under/Healthy 
Weight  
n (%) 
Overweight 
n (%) 
Obese  
n (%) 
Total  
n (%) 
Asthma Severity     
  Mild/Intermittent 13 (11.0) 2 (1.7) 2 (1.7) 17 (14.4) 
  Moderate 56 (47.5) 17 (14.4) 7 (5.9) 80 (67.8) 
  Severe 13 (11.0) 3 (2.5) 5 (4.2) 21 (17.8) 
  Total 82 (69.5) 22 (18.6) 14 (11.9) 118 (100) 
 
 
Reno Population Results 
Associations between Asthma Severity and BMI 
Research Question 1, Hypothesis 1 
Research question 1, hypothesis 1 examined the association between asthma symptom severity 
and elevated BMI. Multinomial logistic regression analysis for asthma severity determined that after 
adjustment, age was the only statistically significant predictor for moderate asthma (AOR 0.78, p=0.003, 
95% CI=0.66-0.92), and severity increased with age for those with severe asthma, though not 
significantly (p=0.420). Increased age (by year) was predictive of a 22% decrease in moderate asthma 
compared to mild or intermittent asthma; therefore as this population gets older, asthma severity lessens, 
at least from the moderate to mild categories. 
Though not statistically significant, compared to healthy weight patients, overweight patients had 
44% higher odds of having moderate asthma (p=0.666) and 40% more likely to have severe asthma 
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(p=0.740). Obese patients were 26% more likely to have moderate asthma (p=0.802) and more than 4 
times more likely to have severe asthma (p=0.162) (Table 12). Race and sex were not significant 
predictors of asthma severity. Adequate model fit was assessed and determined  (Pearson goodness-of-fit 
test, p=0.302, Deviance goodness-of-fit test, p=0.952) (Field, 2013). This result, while not significant 
does show a trend: as BMI is elevated, asthma becomes more severe. If this had been significant, it would 
mean that as public health professionals, it is up to us to see help obese children with asthma to lose 
weight so the severity of their asthma symptoms can decrease. 
 
Table 12. Multinomial Logistic Regression Analysis of BMI Status and Asthma Severity (N=118) 
 Crude odds ratio 
(95% CI) 
p-
value 
Adjusted odds 
ratio (95% CI) 
p-value 
Moderate Asthma*     
BMI Status     
   Healthy weight (<85
th
 percentile)  ‡  ‡  
   Overweight (85
th
 to <95
th
 percentile) 1.97 (0.42-9.62) 0.401 1.44 (0.27-7.66) 0.666 
   Obese (≥95th percentile) 0.81 (0.51-4.37) 0.809 1.26 (0.20-7.88) 0.802 
Age   0.78 (0.66-0.92) 0.003* 
Race     
   Other race    ‡  
   White   1.45 (0.45-4.69) 0.534 
Sex     
   Male   ‡  
   Female   3.16 (0.87-11.46) 0.080 
Severe Asthma*     
BMI Status     
   Healthy weight (85
th
 to <95
th
 
percentile)  
‡  ‡  
   Overweight (≥85th percentile) 1.50 (0.21-10.52) 0.683 1.40 (0.19-10.24) 0.740 
   Obese (≥95th percentile) 2.50 (0.41-15.29) 0.321 4.01 (0.57-28.15) 0.162 
Age   1.08 (0.89-1.32) 0.420 
Race     
   Other race    ‡  
   White   2.07 (0.49-8.80) 0.327 
Sex     
   Male   ‡  
   Female   1.19 (0.40-8.53) 0.426 
*Mild/intermittent asthma is the reference category for asthma status, ‡ reference category 
**Statistically significant at p<0.05 
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Research Question 1, Hypothesis 2 
  Question 1, hypothesis 2 examines the relationship between lung function, as measured by 
spirometry, and elevated body mass. There were no significant differences between BMI categories and 
lung function, although the forced expiratory flow at 25-75% from the ANOVA approached significance 
(p=0.074) (Table 13). The variance was equal in all three models (Levene homogeneity test FEV1% 
p=0.776, FEV1/FCV p=0.321, and FEF25-75% p=0.221) (Field, 2013). 
Table 13. Associations between Weight Category and Pulmonary Function Test 
Measures 
ANOVA F p-value 
FEV1 % 1.21 0.302 
FEV1/FCV  2.23 0.113 
FEF25-75%  2.69 0.074 
 
 
Research Question 1, Hypothesis 3 
 Question 1, hypothesis 3 examines proxy measures of asthma severity in relation to elevated body 
mass. These proxy measures included number of courses of oral steroids required in the past year due to 
asthma, number of emergency department visits in the past year due to asthma, number of school days 
missed in the past year due to asthma, and number of overnight hospitalizations in the past year due to 
asthma. The only proxy measure significantly associated with BMI percentile was oral steroid use 
(2=9.86, p=0.007) (Table 14). 
 
Table 14. Relationships between BMI Status and Asthma Severity Proxies (N=118) 
 BMI Status 
2 p-value 
Number of courses of oral steroids in past year  9.86 0.007* 
Number of emergency department visits in past year 1.78 0.411 
 Fisher exact  p-value 
Number of school days missed in past year  0.624 
Number of overnight hospitalizations in past year  0.108 
*Statistically significant at p<0.05   
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To further examine the significant association between BMI and oral steroid use from the initial 
chi-square test, binary logistic regression was conducted. Table 15 shows that those in the obese category 
have nearly 8 times greater odds of having required at least one course of oral steroids in the past year due 
to asthma (AOR 7.76, p=0.003, 95% CI=2.0-30.11) after adjustment for age, sex, and race/ethnicity. 
Additionally, for each year increase in age, odds of requiring steroids decreased by 22% (Table 15). Race 
and sex were not significant predictors of oral steroid use. Model fit was assessed and determined to be 
adequate (Hosmer and Lemeshow test p=0.630) (Pallant, 2013). This result shows that before visiting a 
pediatric allergist, the obese children in the population likely had poorer asthma control than healthy 
weight or overweight youth, as evidenced by the need for more oral steroids.  
 
Table 15. Binary Logistic Regression Analysis of BMI Status and Oral Steroid Use (N=118) 
 Crude odds ratio 
(95% CI) 
p-value Adjusted odds 
ratio (95% CI) 
p-value 
BMI Status     
   Healthy weight (<85
th
 percentile)  ‡  ‡  
   Overweight (85
th
 to <95
th
 
percentile) 
2.01 (0.77-5.28) 0.155 1.80 (0.66-4.85) 0.249 
   Obese (≥95th percentile) 6.04 (1.73-21.16) 0.005** 7.76 (2.0-30.11) 0.003* 
Age   0.88 (0.78-0.99) 0.027* 
Race     
   White    ‡  
   Other race   0.90 (0.39-2.10) 0.812 
Sex     
   Female   ‡  
   Male   0.79 (0.34-1.88) 0.249 
*Significant at p<0.05, ‡ reference category 
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Associations between Allergic Sensitization and BMI 
Research Question 2 
 Research question 2, hypothesis 1 examines elevated BMI and allergic sensitization and 
polysensitization. The binary logistic regression model for allergen sensitization demonstrated BMI and 
age were significant predictors of allergen sensitization. Overweight patients were 79% less likely to be 
sensitized to allergens than those who were of healthy weight (AOR 0.21, p=0.010, 95% CI=0.06-0.69). 
Additionally, for each year increase in age, all patients had 28% greater odds of being sensitized to 
allergens (AOR 1.28, p=0.010, 95% CI=1.06-1.54) (Table 16). 
Binary logistic regression for polysensitization demonstrated that BMI and age were significant 
predictors for polysensitization. Overweight patients were 73% less likely to be polysensitized than those 
who were of healthy weight (AOR 0.27, p=0.028, 95% CI=0.09-0.87) (Table 17). For each year increase 
in age, this population had 27% greater odds of being polysensitized to aeroallergens (AOR 1.27, 
p=0.006, 95% CI 1.07-1.50). Obese BMI percentile status, race, and sex were not associated significantly 
with atopy or polysensitization (Tables 16 & 17). Both models were assessed and yielded adequate model 
fit (Hosmer and Lemeshow test for allergen sensitization model, p=0.719; Hosmer and Lemeshow test for 
polysensitization model, p=0.887) (Pallant, 2013). 
These results show that increases in age are associated with increased in allergen sensitization – 
this is logical; as a child gets older he or she will be exposed to more allergens. These results also show 
that overweight (but not obesity) is associated with lower allergen sensitization, although all children 
were sensitized, therefore all children should be tested for allergies if they have asthma because 
sensitization does occur in all weight status categories. 
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Table 16. Binary Logistic Regression Analysis of BMI Status and Allergen Sensitization (N=118) 
 Crude odds ratio 
(95% CI) 
p-
value 
Adjusted odds 
ratio (95%CI) 
p-value 
BMI Status     
   Healthy weight (<85
th
 percentile)  ‡  ‡  
   Overweight (85
th
 to <95
th
 
percentile) 
0.19 (0.06-0.61) 0.005* 0.21 (0.06-0.69) 0.010* 
   Obese (≥95th percentile) 0.67 (0.13-3.53) 0.633 0.46 (0.08-2.84) 0.407 
Age   1.28 (1.06-1.54) 0.010* 
Race     
   White    ‡  
   Other race   1.70 (0.50-5.78) 0.369 
Sex     
   Female   ‡  
   Male   1.44 (.46-4.52) 0.537 
*Statistically significant p<0.05, ‡ reference category 
 
 
Table 17. Binary Logistic Regression Analysis of BMI Status and Allergen Polysensitization 
(N=118) 
 Crude odds ratio 
(95% CI) 
p-
value 
Adjusted odds 
ratio (95%CI) 
p-value 
BMI Status     
   Healthy weight (<85
th
 percentile)  ‡  ‡  
   Overweight (85
th
 to <95
th
 
percentile) 
0.25 (0.08-0.75) 0.013* 0.27 (0.09-0.87) 0.028* 
   Obese (≥95th percentile) 0.52 (0.12-2.21) 0.378 0.37 (0.08-1.81) 0.221 
Age   1.27 (1.07-1.50) 0.006* 
Race     
   White    ‡  
   Other race   1.18 (0.40-3.43) 0.771 
Sex     
   Female   ‡  
   Male   1.33 (0.45-3.90) 0.603 
*Statistically significant p<0.05, ‡ reference category 
 
 
Children’s Heart Center Population – Demographics & Descriptive Characteristics  
 The Children’s Heart Center Healthy Hearts Program population was comprised of 232 patients, 
of whom, 54.3% were male (n=126), 64.2% were Hispanic (n=149), and 55.2% received Medicaid 
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(n=128). Most children participated the program in Las Vegas (91.4%, n=212), however between 2006 
and 2009, 20 children (8.6%) participated in the program in Reno. The Reno location is no longer 
participating in the HHP. The mean age of the population was nearly 11 years old with a range from 
approximately 6.5 years to 18 years old (Table 18). Eighty-six children (37.1%) had asthma, and 146 
(62.9%) did not have asthma, while 18.1% of this population had allergies to aeroallergens, food 
allergens, medications, or a mixture of allergens (Table 18). The median time in the program was 9 
weeks, with a range of 1-12 weeks (Table 18). 
 Nearly 98% of the HHP population had at least one diagnosis (not including asthma, which was 
not counted as a “comorbid” diagnosis as asthma status was it’s own variable). Only four patients did not 
have an existing diagnosis; one only had an asthma diagnosis (Table 18). Forty-seven percent of the 
population (n=109) had two coexisting diagnoses, 22% (n=51) had three coexisting diagnoses and 23 
children (10%) had four or more coexisting diagnoses in their records. Metabolic diagnoses include those 
with International Classification of Disease, 9
th
 revision (ICD-9) codes from 240-279: Endocrine, 
nutritional and metabolic diseases, and immunity disorders, or ICD 10 codes E00-E89: Endocrine, 
nutritional or metabolic diseases. These include diagnoses of metabolic syndrome, diabetes mellitus, 
elevated lipid, cholesterol or insulin levels, and obesity (CDC, 2015d; WHO, 2016). Metabolic syndrome 
was the most common metabolic disease in this population (n=140, 60.3%). Non-metabolic diseases in 
this population were mainly, hypertensive or heart diseases or functional murmur (n=56, 24.1%), and/or 
congenital heart conditions that did not prevent the child from participating in the intervention (n=20, 
8.6%). The number of comorbid diagnoses differed significantly between the asthmatic (median 2 
diagnoses) and non-asthmatic groups (median 1 diagnosis) (Mann-Whitney U=5235.0, p=0.022). The 
variable was added as a covariate to all further multivariable analyses, but it did not end up in any final 
models, as it was not significant in any adjusted models. 
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Table 18. Population Characteristics of Children’s Heart Center Patients (N=232) 
 Variable Non-Asthmatic 
n(%) 
Asthmatic n(%) Total n (%) 
Sex    
   Male 75 (32.2) 51 (22.0) 126 (54.3) 
   Female 71 (30.6) 35 (15.1) 106 (45.7) 
Race/Ethnicity    
   Black/African-American 16 (6.9) 12 (5.2) 28 (12.1) 
   Hispanic 96 (41.4) 53 (22.8) 149 (64.2) 
   White 24 (10.3) 15 (6.5) 39 (16.8) 
   Other 10 (4.3) 6 (2.6) 16 (6.9) 
Insurance Status    
   Private Insurance 66 (28.4) 28 (12.1) 94 (40.5) 
   Medicaid 73 (31.5) 55 (23.7) 128 (55.2) 
   No Insurance 7 (3.0) 3 (1.3) 10 (4.3) 
Location    
   Las Vegas 129 (55.6) 83 (35.8) 212 (91.4) 
   Reno 17 (7.3) 3 (1.3) 20 (8.6) 
Allergies    
   Yes 16 (6.9) 26 (11.3) 42 (18.2) 
      Food or Aeroallergens    4 (1.7)    9 (3.9)    13 (5.6) 
      Medication    9 (3.9)    12 (5.2)    21 (9.1) 
      Multiple categories    3 (1.3)    5 (2.2)    8 (3.4) 
   No 120 (51.7) 60 (25.9) 180 (77.6) 
   Unknown 10 (4.3) 0 (0) 10 (4.3) 
Comorbid diagnoses    
   Yes 142 (61.1) 85 (36.6) 227 (97.8) 
      Metabolic diagnosis (1 dx*)    78 (33.6)    46 (19.8)    124 (53.4) 
      Metabolic + other diagnosis      
     (1dx*) 
   40 (17.2)    31 (13.4)    71 (30.6) 
      Other diagnosis (1dx*)    24 (10.3)    8 (3.4)    32 (13.8) 
   No 4 (1.7) 1 (0.4) 5 (2.2) 
 Non-asthmatic 
(mean, SD) 
Asthmatic  
(mean, SD) 
Total 
(mean, SD) 
Age (years) range: 6.44-18.02 10.57 (2.418) 11.26 (2.621) 10.83 (2.512) 
 Non-asthmatic 
(med, range) 
Asthmatic  
(med, range) 
Total  
(med, range) 
Weeks in program 9.00 (1-12) 8.00 (1-12) 9.00 (1-12) 
*Abbreviation: dx= diagnosis 
 
 
Crude baseline outcome measures from the intervention program are shown with follow-up 
measures, and stratified by asthma status in Table 19. Differences between pre (week 1) and post (week 
12) measures were examined with paired t-tests or Wilcoxon signed ranks tests depending on whether the 
variable was normally distributed or not (Pallant, 2013). Means with standard deviation and mean 
changes are reported for all variables in Table 19. 
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 Among the population with asthma, BMI percentile decreased significantly (mean change =-
0.26, p<0.042) from 98.14 pre-intervention to 97.88 post-intervention. BMI z-score also decreased 
significantly mean change=-0.05 p<0.002) from 2.25 at week 1 to 2.20 at week 12. Non-asthmatic 
children also had a significant decrease in BMI percentile (mean change=-0.28 (p=0.002) from 98.44 pre-
intervention to 98.16 post-intervention, and a significant decrease in BMI z-score (mean change=-0.05, 
p=0.001) from 2.36 pre-intervention to 2.31 post intervention (Table 18). VO2 max levels increased 
significantly for both males with asthma from 34.48 mL/Kg/min to 38.65 mL/Kg/min (mean 
change=4.17, p=0.003) and females with asthma, from 26.00 mL/Kg/min to 29.79 mL/Kg/min (mean 
change=3.79, p<0.001). Among patients without asthma, VO2 max levels for males also increased 
significantly (mean change=6.17,p<0.001) from 32.29 mL/Kg/min to 38.46 mL/Kg/min. VO2 max levels 
for females without asthma also increased significantly (mean change =5.0, p<0.001) from 25.75 
mL/Kg/min at week 1 to 28.84 mL/Kg/min at week 12 (Table 19). 
Exercise intensity, or metabolic equivalents (METs) increased significantly for patients with 
asthma from 3.49 pre-intervention to 3.79 post-intervention (mean change = 0.30, p=0.033), and for those 
without asthma from 3.29 at week 1 to 3.58 at week 12 (mean change=0.29, p<0.001). Heart rate also 
increased significantly for asthma patients (mean change=8.37, p=0.002), but not for youth without 
asthma. Blood pressure did not change significantly from pre- to post-intervention in either asthma group 
(Table 19). 
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Table 19. Comparison of Pre- and Post-test Scores of Select Outcomes from Healthy Hearts Program 
Participants with and without Asthma (N=232) 
 Participants with Asthma Participants without Asthma 
 N Mean (SD) 
 
Mean change 
week 1-12  
(1-tailed p) 
N Mean (SD) 
 
Mean change 
week 1-12  
(1-tailed p) 
BMI Percentile       
   Week 1  86 98.14 (1.125) -0.26 (0.042)*
a
 146 98.44 (1.213) -0.28 (0.002)*
a
 
   Week 12 43 97.88 (1.665)  91 98.16 (1.797)  
BMI z-score       
   Week 1  86 2.25 (0.372) -0.05 (0.002)*
b
 146 2.36 (0.338) -0.05 (0.001)*
a
 
   Week 12 43 2.20 (0.394)  91 2.31 (0.375)  
Vo2Max  
(mL/Kg/min) 
      
   Week 1 – Male  39 34.48 (5.916) 4.17 (0.003)*
b
 63 32.29 (8.150) 6.17 (<0.001)*
b
 
   Week 12 – Male  21 38.65 (6.803)  38 38.46 (4.766)  
   Week 1 – Female  25 26.00 (6.773) 3.79 (0.004)*
b
 65 23.75 (8.133) 5.09 (<0.001)*
b
 
   Week 12 – Female  19 29.79 (7.004)  42 28.84 (6.640)  
Metabolic 
Equivalents 
(METs) 
      
   Week 1  10 3.49 (0.273) 3.00 (0.033)*
b
 82 3.29 (0.427) 0.29 (<0.001)*
b
 
   Week 12 7 3.79 (0.422)  55 3.58 (0.480)  
Pre-activity heart 
rate (BPM) 
      
   Week 1  77 95.04 (13.633) 8.37 (0.002)*
b
 131 99.98 (15.042) 0.40 (0.388)
b
 
   Week 12 42 103.41 (13.111)  80 100.38 (13.478)  
Pre-activity systolic 
blood pressure 
(mmHg) 
      
   Week 1  80 115.35 (12.424) 0.44 (0.347)
a
 143 114.71 (11.643) -0.86 (0.388)
a
 
   Week 12 43 115.79 (13.041)  87 113.85 (11.218)  
Pre-activity 
diastolic blood 
pressure (mmHg) 
      
   Week 1  79 65.57 (9.469) 0.69 (0.277)
a
 142 65.63 (8.443) 0.72 (0.204)
a
 
   Week 12 43 66.26 (10.248)  87 66.35 (10.285)  
* Statistically significant at p<0.05 (1-tailed); 
a
 significance measured by Wilcoxon signed rank test; 
b
 
significance measured by paired t-test 
 
Additionally, crude changes between those with and without first at baseline and separately at 
post-intervention were examined on the same measures using independent t-tests or Mann-Whitney U 
tests (depending on the variable’s distribution) (Pallant, 2013). The only statistically significant finding 
between the groups was the post-intervention BMI percentile. Those with asthma had a mean post-
intervention BMI percentile of 97.88 (SD 1.665) while those without asthma had a post-intervention BMI 
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percentile of 98.16 (SD 1.797) (p=0.041). The median BMI percentile was 99
th
 percentile for both groups 
post intervention. All other pre- or post-intervention measures did not yield statistically significant 
differences between children with and without asthma (Table 20). 
Pre-intervention laboratory test results for cholesterol, triglycerides, C-reactive protein, and 
insulin were available for 19-53% of the population (depending on the test). Post-test values were 
available/and or required for only 10-15% of the total CHC population. As stated in the methods section, 
post-intervention laboratory tests are conducted only when the pre-tests are abnormal. Therefore, the post-
test values are from the least healthy 10-15% of the population. Along with the low number of test results 
obtained from medical records, this may have contributed to bias and therefore are not included in the 
analyses.  
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Table 20. Differences between Healthy Hearts Program Participants with and without Asthma at 
Baseline (Week 1) and Post-intervention (Week 12) (N=232) 
 Baseline Post-intervention 
 N Mean (SD) 
 
Mean 
difference 
(p) 
N Mean (SD) 
 
Mean 
difference 
(p) 
BMI Percentile       
   Asthma 86 98.24 (1.127) 0.12 (0.132)
a
 43 97.88 (1.665) 0.28 (0.041)*
a
 
   No Asthma 146 98.36 (1.423)  91  98.16 (1.797)  
BMI z-score       
   Asthma 86 2.29 (0.360) 0.05 (0.141)
a
 43 2.20 (0.394) 0.11 (0.050)
a
 
   No Asthma 146 2.34 (0.339)  91 2.31 (0.374)  
Vo2Max  
(mL/Kg/min) 
      
   Asthma – Male 39 34.30 (7.234) -2.83 (0.419)
b
 21 38.69 (6.634) -2.02 (0.990)
b
 
   No Asthma –Male 63 31.47 (8.279)  38 36.67 (4.850)  
   Asthma – Female  25 26.74 (7.358) -2.91 (0.152)
a
 19 29.79 (7.004) -1.08 (0.565)
b
 
   No Asthma – F 65 23.83 (6.854)  42 28.71 (6.608)  
Metabolic Equivalents 
(METs) 
      
   Asthma 10 3.51 (0.233) -0.26 (0.073)
b
 7 3.79 (0.422) -0.23 (0.241)
b
 
   No Asthma 82 3.25 (0.436)  55 3.56 (0.476)  
Pre-activity heart rate 
(BPM) 
      
   Asthma 77 95.75  (12.785) 5.84 (0.149)
b
 42 103.40 (13.478) -3.02 (0.236)
b
 
   No Asthma 131 101.59 (15.99)  80 100.38 (13.111)  
Pre-activity systolic 
blood pressure 
(mmHg) 
      
   Asthma 80 115.24 (40.915) -1.11 (0.514)
a
 43 115.97 (13.041) -2.12 (0.628)
b
 
   No Asthma 143 114.13 (11.98)  87 113.85 (11.218)  
Pre-activity diastolic 
blood pressure 
(mmHg) 
      
   Asthma 79 64.20 (8.379) 2.43 (0.069)
a
 43 66.12 (10.170) 0.23 (0.631) 
   No Asthma 142 66.63 (8.717)  87 66.35 (10.285)  
* Statistically significant at p<0.05 (2-tailed); 
a
 significance measured by Mann-Whitney U test; 
b
 
significance measured by independent samples t-test 
 
Children’s Heart Center Results 
Outcomes from the Healthy Hearts Program Intervention 
Research Question 3 
Cox regression analysis was performed to examine attrition between the participants with and 
without asthma in the CHC Healthy Hearts Program. There was no significant difference between the two 
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groups (p=0.300), nor were any other variables statistically significant (Table 21). This indicates that 
asthmatic children were able to successfully complete the intervention compared with the non-asthmatic 
group. This suggests that the intervention could be a feasible approach for weight loss and lung function 
improvement, even among youth experiencing respiratory distress.  A final adjusted model was also 
performed with age (1% contribution) and ethnicity (5% contribution) removed as they did not contribute 
much to the model. The model was not significantly improved; these data are not shown. No covariates 
violated the proportional hazards assumption, and each variable was checked by time dependent covariate 
in SPSS (T_*variable) as well by visual examination of log minus log plots (Hosmer, Lemeshow, & May, 
2008). 
 
Table 21. Attrition among the Children’s Heart Center Healthy Hearts Program 
Participants (N=165) 
 Crude Hazard 
Rate (95% CI) 
p-value Adjusted Hazard 
Rate (95%CI) 
p-value 
Asthma     
   Yes ‡  ‡  
   No 0.79 (0.52-1.14) 0.207 0.82 (0.56-1.19) 0.300 
Age   1.01 (0.94-1.07) 0.860 
Race/Ethnicity     
   Non-Hispanic   ‡  
   Hispanic   0.80 (0.55-1.17) 0.251 
Sex     
   Female   ‡  
   Male   1.05 (0.74-1.49) 0.792 
Insurance Status     
   Insured   ‡  
   Medicaid   1.24 (0.87-1.77) 0.236 
‡ reference category 
 
Power analyses were conducted; the sample size was adequate to run all ANOVA models with 
95% power. Program outcomes for weight loss (BMI z-score) and cardiorespiratory health, specifically 
maximal oxygen uptake (VO2 max) were examined using repeated measures ANOVA models; covariates 
were then added to the models.  
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In the BMI model, the assumption of sphericity was violated as demonstrated by Mauchly’s test 
of sphericity, 2(2)=94.20, p<0.001. Accordingly, the Greenhouse-Geisser estimate of sphericity 
 used to correct the degrees of freedom. Time in the program is the only variable which 
significantly affected change in BMI z-score, F(1.3, 166.4)=5.33, p=0.014 (Table 22). There was an 
inverse association between BMI z-score and time in the program. The mean z-score at week 1= 2.314, 
and the mean z-score at week 12= 2.265. This result shows that after adjustment for all covariates, the 
mean BMI significantly decreased among the HHP population. 
 
Table 22. Weight loss in the Healthy Hearts Program Population Represented by BMI z-score 
(N=133) 
 Crude model Adjusted model 
 F (p) Effect size F (p) Effect size 
Time in Program (weeks) 27.20 
(<0.001)* 
0.172 5.33 
(0.014)* 
0.040 
Asthma (y/n) 0.047 (0.888) <0.001 0.01 (0.951) <0.001 
Age in years   0.64 (0.463) 0.005 
Race/Ethnicity (Hispanic/Non-
Hispanic) 
  0.50 (0.529) 0.004 
Sex (m/f)   2.13 (0.141) 0.016 
Insurance status   0.27 (0.665) 0.002 
*Statistically significant p<0.05 
 
 
 For VO2 max, the population was stratified by sex, as the values for VO2 increase differently for 
boys and girls when they reach puberty. As stated earlier, while the values increase with greater oxygen 
uptake and better cardiorespiratory health, the values continue to increase as age in males increases, 
however, the values begin to decrease as female age increases with regard to each specific health category 
as described in the FITNESSGRAM® standards outlined in detail in Chapter 2, page 39 (Meredith & 
Welk, 2013). 
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 The assumption of sphericity was not violated in any VO2 max models; therefore degrees of 
freedom did not need to be corrected. In both the male and female unadjusted models, time in the program 
significantly affects VO2 max: males F(1, 54)=30.49, p<0.001; females F(1, 58)=20.41, p<0.001. 
However, in the adjusted models for both males and females, none of the variables were associated with 
VO2 max (Tables 23 and 24). 
 
Table 23. Cardiorespiratory Health Changes in the Healthy Hearts Program Population as 
Represented by VO2 max for the Male Population (N=133) 
 Crude model Adjusted model 
 F (p) Effect size F (p) Effect size 
Time in Program (weeks) 30.49 (<0.001)* 0.361 2.36 (0.130) 0.044 
Asthma (y/n) 1.16 (0.287) 0.021 1.28 (0.263) 0.024 
Age in years   2.89 (0.095) 0.054 
Race/Ethnicity (Hispanic/Non-
Hispanic) 
  1.49 (0.121) 0.046 
Insurance status   0.82 (0.368) 0.016 
*Statistically significant p<0.05 
 
 
Table 24. Cardiorespiratory Health Changes in the Healthy Hearts Program Population as 
Represented by VO2 max for the Female Population (N=133) 
 Crude model Adjusted model 
 F (p) Effect size F (p) Effect size 
Time in Program (weeks) 20.41 (<0.001)* 0.260 0.03 (0.855) 0.001 
Asthma (y/n) 0.44 (0.510) 0.008 0.20 (0.655) 0.004 
Age in years   0.03 (0.854) 0.001 
Race/Ethnicity (Hispanic/Non-
Hispanic) 
  2.58 (0.114) 0.045 
Insurance status   0.01 (0.919) 0.000 
*Statistically significant p<0.05 
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CHAPTER 5. DISCUSSION 
 The objectives of this study were 1) to examine the relationship between asthma/allergy and 
obesity and how these conditions affect each other in two pediatric Nevada populations, and 2) to 
evaluate a 12-week physical activity and nutrition intervention for children at risk for heart disease to 
determine if the intervention was also feasible for children who have asthma. It was predicted that youth 
with elevated BMI would have more severe asthma symptoms, decreased lung function, and poorer 
quality-of-life proxy measures for asthma severity than those at a healthy weight. It was predicted that 
there would be a difference in atopy among those with elevated BMI and those with healthy BMI. It was 
also hypothesized that children with asthma would have higher attrition and poorer outcomes in the 
intervention program.  
 
Discussion & Interpretation of Research Questions 
Research questions 1 and 2 regarding asthma and allergies and the effect of BMI utilized data 
provided by the Reno clinic population (N=125). These children had a median age of 7 years, were 
approximately 60% male and nearly 65% white. Nearly one-third of the Reno population was in the 
overweight (85
th
 to <9
th
 BMI percentile category) or obese (≥95th BMI percentile category). This 
population had many children in the severe or moderate asthma symptom categories at diagnosis, and was 
highly atopic with a median of 11 allergens to which the population was sensitized. Nearly 40% had 
required at least one course of oral steroids in the past year, and 25% had required a visit to the 
emergency department in the past year due to asthma. 
 This study did find more severe asthma in those with elevated BMI, though this measure was not 
statistically significantly higher. The spirometric measures of lung function did not differ between groups. 
The quality-of-life proxy measures for asthma severity were oral steroid courses required, 
hospitalizations, ED visits, and school days missed all in the past year due to asthma. Oral steroid use was 
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significantly associated with BMI category; further analysis demonstrated that obesity was a predictor of 
the need for oral steroids. 
Research question 1, hypothesis 1 tested the association between asthma symptom severity and 
elevated BMI in the Reno pilot study population. While none of the BMI percentile groups were 
statistically significant in this population, those with BMI values in the obese category were more than 
four times more likely to have severe asthma compared to mild asthma The p-value was not statistically 
significant (p=0.162), however the confidence interval was relatively large with the lower bound close to 
one (95% CI 0.57 to 28.15). This large interval could be indicative of a true effect that is not evident due 
to the small sample of obese youth (n=14) even though the model was appropriate as evidenced by 
goodness-of-fit tests (Hennekens & Buring, 1987; Pallant, 2013).   
The literature demonstrates a clear link between increased weight and more severe asthma due to 
many factors including excess weight upon the chest, increased inflammation in the airways, and 
decreased effectiveness of common corticosteroid medications (Black et al., 2013; Dixon et al., 2010; 
Kim, Sutherland & Gelfand, 2014; Sutherland 2014). While the first alternative for question 1 must be 
rejected, due to the lack of a significant association between asthma severity and obesity, the possibility 
of a true association should not be ruled out (Hennekens & Buring, 1987), rather tested with a larger 
sample of obese, asthmatic, and atopic youth in Nevada. 
Question 1, hypothesis 2 examined the relationship between lung function as measured by 
spirometry, and BMI percentile in the Reno population. FEV1%, FEV1/FCV, and FEF25-75% were all tested 
in separate one-way ANOVAs. The hypothesis must be rejected; none of the measures were statistically 
significant, although FEF25-75% did approach significance (p=0.074). FEF25-75% is the pulmonary function 
test believed to be the most sensitive for children, (Ciprandi et al., 2012; Spaulding et al., 2012). 
This finding is inconsistent with the academic literature demonstrating significantly poorer lung 
function in children who are obese (Jensen, Gibson, Collins, & Wood, 2013; Krishnan, Hettiaracchi, 
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Scharbach, & Dozor, 2016; Vinding, Stockholm, Chawes & Bisgaard, 2016). Although the samples 
among groups were adequate according to Levene’s test of homogeneity (Field, 2013), it is still possible 
that the number of obese youth was too small to detect a true effect. Additionally, this population may 
simply not have had poorer lung function among the overweight or obese children. 
Question 1, hypothesis 3 tests the associations between proxy measures of asthma severity in 
relation to elevated body mass. These measures included number of courses of oral steroids required in 
the past year due to asthma, number of emergency department visits in the past year due to asthma, 
number of school days missed in the past year due to asthma, and number of overnight hospitalizations in 
the past year due to asthma. The only measure significantly associated with BMI percentile was oral 
steroid use, therefore multiple logistic regression analysis was conducted to further examine this 
association. After adjustment for age, race, and sex, the odds of requiring at least one course of oral 
steroids among the obese patients was nearly 8 times greater than for the patients at healthy weight 
(p=0.003). The children in this population were assessed at the initial visit, as previously noted. This may 
indicate a potential view of the natural progression of symptoms in children with poorly managed asthma 
(Lucas, Moonie, Olsen-Wilson, & Hogan, 2016). 
Prescription of long-term oral steroids is no longer common practice, as newer ICS medications 
are more potent, thus requiring smaller doses, and safer than oral steroids which can lead to numerous 
metabolic and other issues including weight gain. Generally oral steroids are now only used for control in 
severe, persistent cases of asthma (NHLBI, 2007; Reddy et al., 2014). However, inhaled corticosteroids 
have decreased effectiveness in obese patients, leading to poorer control of asthma and the need for oral 
steroids (Baffi et al., 2015; Forno et al., 2011; Sutherland, 2014). While the other proxy measures were 
not significantly associated with elevated BMI in this population, oral steroid use was, which is consistent 
with current literature. 
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Research question 2 tested the associations between elevated BMI and allergen sensitization and 
polysensitization. The analysis of the Reno population showed that overweight youth with asthma had 
nearly 80% lower odds of being sensitized to allergens than healthy weight patients (p=0.010), and 73% 
lower odds of being polysensitized than those in the healthy weight BMI percentile category. Obese youth 
also had lower odds of both sensitization and polysensitization compared to healthy weight children, 
although not significantly lower (p=0.407 and p=0.221, respectively). 
While asthma severity and obesity have an established link in literature (Black et al., 2013; Dixon 
et al., 2010; Sutherland 2014), research regarding allergen sensitization and overweight/obesity is 
conflicted. Some research has found positive associations between atopy and elevated weight status (Loid 
et al., 2015). Other studies have determined that there is no association between atopy and obesity (Ali & 
Ulrick, 2013; Jensen et al., 2011; Jensen et al, 2012). Research consistent with this study found negative 
associations between allergic sensitization and elevated weight status in children (Han, Forno, Gogna, & 
Celedon 2016; Lucas et al., 2016).  The lower odds of allergen sensitization may also be due to the 
Th1/Th2 imbalance found in some obese asthmatics due to excess adipokines that trigger an innate (Th1-
favoring) immune response rather than the allergic (Th2) response associated with allergic asthma 
(Ignacio et al. 2014; Raj et al, 2014; Rastogi et al., 2014). 
Worldwide, approximately 10-30% of people are atopic, and in the U.S approximately 10% of 
white children and 7% of black children have atopy (AAAAI, 2016). However, the presence of atopy in 
nearly the entire Reno population suggests that the Great Basin climate may play a role in the allergic risk 
factors for asthma. Sensitization to specific allergens such as pine and willow trees, and sagebrush and 
pigweed is common to this region, but not the rest of the country (Wong, 2012). 
The third research question utilized data from the second population comprised of children who 
participated in the HHP (N=232). The children in this population were all overweight or obese, and 37% 
also had asthma. The mean age of the participants was nearly 11 years old. Slightly more than half of this 
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population was male (54%), 64% were of Hispanic ethnicity, and more than half of the population 
received Medicaid. Almost every child in this population (97.8%) had at least one diagnosis (other than 
asthma), the majority of which were metabolic disorders (metabolic syndrome, diabetes mellitus type 2, 
etc.) or heart or hypertensive conditions; more than half of the population suffered from more than one 
coexisting condition. 
Unadjusted analyses of program outcomes showed significant decreases in BMI percentile and z-
score for children with and without asthma, as well as increases in cardiorespiratory health (VO2 max) 
and exercise intensity (METs) in both groups. Crude analyses looking at baseline and post-intervention 
differences between children with and without asthma found that the only measure significantly different 
was BMI percentile post-intervention; it was 0.28 percentile lower in the asthmatic population (p=0.041). 
These results, measured by t-tests and non-parametric equivalents could potentially be indicative of a 
program that is not only possible for children with asthma to participate in with their non-asthmatic peers, 
but is significantly beneficial as evidenced by decreased BMI, increased cardiorespiratory health, and the 
ability to increase exercise intensity. 
In multivariable evaluation of the CHC HHP, attrition was not significantly different between 
youth with and without asthma, indicating further that the program could be practical for those with 
asthma, as they do not quit at higher rates than the non-asthmatic participants. The patients with asthma 
also have a likely probability of EIB and they had significantly more comorbid disorders than the non-
asthmatic patients.  
The outcome measure weight loss (measured using BMI z-score), when adjusted for age, 
ethnicity, sex, and insurance status was not significantly different between children with and without 
asthma. The only significant measure was time in the program – the mean BMI decreased if participants 
stayed in the program longer. The outcome measure VO2 max, stratified by sex and analyzed in two 
separate models, had no significant associations after adjustment for age, ethnicity, and insurance status.  
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Numerous studies have found that weight loss is essential to the improvement of symptoms in 
obese asthmatics, as are other benefits from physical activity such as improved cardiorespiratory and 
cardiovascular health and improved mental health (Abd El-Kader et al., 2013; Dixon et al., 2010; 
Sutherland, 2014). Programs tailored for asthmatics are recommended to help increase physical activity 
for youth who have asthma (Wanrooij, 2014). A program, such as the Healthy Hearts Program, which 
appears to benefit children with asthma, could be a way to increase physical activity in more Nevadans 
who have asthma, thus decreasing the severity of asthma symptoms. 
 
Public Health Impact and Policy Recommendations 
 The availability of clinical data provided an opportunity to use epidemiological study designs to 
examine problems faced by patients with asthma and obesity and the physicians who treat them, in a way 
that can be translated to clinicians. For instance, the high atopic prevalence in obese youth, which is not 
common in obese children with asthma, demonstrates a possible need for recommendations for clinicians 
to test obese youth for allergen sensitization. In addition, this study also contributed to gaps in research 
regarding pediatric asthma, allergies, and obesity in a climate conducive to aeroallergen sensitization 
(Lucas et al., 2016). This research may be beneficial to public health professionals in need of knowledge 
and intervention strategies to help with both weight loss and asthma control on a larger scale than the 
individual clinical level. 
While the high degree of atopy in the Reno population may result in a lack of generalizability, the 
findings could be useful for other areas of the country with high allergen sensitization, for example, the 
Southeast U.S., which has the highest prevalence of both indoor aeroallergen and food allergen 
sensitization, as well as high rates of childhood obesity (Salo et al., 2014; DNPAO, 2015). While 
generalizability is certainly an important epidemiological concept (Gordis, 2014; Hennekens & Buring, 
1987), chronic conditions such as asthma and obesity will not necessarily be generalizable. Conditions 
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that affect people in different ways based on different factors, from genetics to environmental conditions 
to socioeconomic factors, may not be generalizable to the entire U.S or world population. Yet research 
into these conditions still adds to academic literature. Causality of disease is also part of the backbone of 
epidemiology (Gordis, 2014; Hennekens & Buring, 1987; Hulley, Cummings, Browner, Grady, & 
Newman, 2007). However, trying to find definitive cause for conditions with as many risk factors as 
asthma and obesity is extremely difficult, maybe impossible. In some cases, perhaps the most beneficial 
public health research is not to try and find cause, rather to focus on how these conditions impact the 
health of communities, and to focus on disparities that can be lessened or even eliminated. This study 
does examine who is impacted by asthma and obesity in Nevada, and assesses methods to lessen the 
burden. 
The Children’s Heart Center’s Healthy Hearts Program appears to be feasible and beneficial for 
obese asthmatic youth. This program has existed since 2002. It is a private program run by the Children’s 
Heart Center and requires referrals from other doctors, but it is a program that already exists. There are 
already protocols and there is already equipment and a place for activity as well as offices with 
nutritionists who meet with families to provide education and advice. This program has already been 
helpful to many Nevada children at risk for heart disease, with and without asthma. This program design 
could also serve as a helpful model or template for similar programs in other Nevada areas besides Las 
Vegas, or even in other states. Follow up studies should be expanded to larger populations, particularly 
those at greater risk of morbidity and mortality. For example, this intervention could be feasibly expanded 
to those of minority status and the uninsured with appropriate funding, such as through the CDC’s 
National Asthma Control Program (NACP), Medicaid, or private insurance companies.  
Furthermore, many children do not have safe neighborhoods in which to do physical activity 
(IOM, 2012;waters et al., 2011). While it is possible to do activities indoors, children tend to enjoy 
activity more and choose to participate when encouraged by peers (Herbert, Lohrmann, Seo, Stright, & 
Kolbe, 2013; Lorusso, Pavlovich, & Lu, 2013). Partnering with schools, school-based after-school 
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programs, or after-school programs though community-based non-profit organizations could provide a 
place to expand intervention programs. 
Healthy People 2020 is a health promotion initiative from the Office of Disease Prevention and 
Health Promotion (ODPHP) through the U.S. Department of Health and Human Services that provides 
10-year goals for health promotion and disease prevention (ODPHP, 2016a). One of the objectives 
regarding respiratory health is to reduce limitations to activity in people with asthma. Another one is to 
increase the number of states with comprehensive asthma surveillance programs (ODPHP, 2016b). These 
Healthy People 2020 initiatives demonstrate that there are currently already goals to increase physical 
activity in people with asthma, and this study has a good intervention program for asthmatic children. 
Nevada does not currently receive federal funding from the CDC’s NACP, a program that helps 
with state and local level asthma surveillance and education (CDC, 2015b). With a sustainable program 
such as the HHP, which is available to Nevada children with obesity and asthma, Nevada should apply for 
funding from the CDC’s NACP. This could help Nevada asthmatics have better health, and it would 
contribute to the Healthy People 2020 nationwide goal of more comprehensive asthma surveillance. 
 
Study Limitations 
This study had a number of limitations. Among the Reno pilot population, the high amount of 
allergen sensitization meant that the population may have been be too similar and not be truly 
representative of obese asthma patients elsewhere. The population was also nearly 65% white, which is 
also not necessarily generalizable. Additionally, BMI percentile categories were used as a measure of 
weight status. BMI is not always the most accurate measure of weight as there is no way to distinguish fat 
mass from healthy lean mass, such as muscle (Shah & Braverman, 2012; Romero-Corral et al., 2008).  
This could lead to non-differential misclassification of cases. The pilot dataset also did not include 
birthdate, height, and weight data due to IRB requirements so BMI z-scores could not be calculated and 
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the BMI percentiles had to be categorized, which can result in a lack of statistical power as well as the 
inability to conduct specific statistical analyses (Field, 2013).  
While the pilot population had BMI category groups large enough for appropriate statistical tests 
(Field, 2013; Pallant, 2013), the practical breakdown of the groups (nearly 70% of the population were 
healthy weight) could have led to smaller than ideal sample sizes among the groups, and potential missed 
findings as evidenced by large confidence intervals with small group sizes (Hennekens & Buring, 1987). 
The potential non-differential misclassification may also dilute results (Gordis, 2014), leading to an even 
stronger possibility that severe asthma is truly associated with obesity, although the p-value was not 
significant. 
The CHC data also had limitations. The data were collected using electronic medical records 
systems. They were secondary data originally collected as part of regular procedure for the hospital or the 
Healthy Hearts Program. While some data were electronic, other data were handwritten on scanned 
forms. Data errors were evaluated by myself as well as by the Research Director of Children’s Heart 
Center, and numerous staff members were available for questions, yet information bias, specifically 
differential misclassification, could still exist (Gordis, 2014). Multiple people originally collected the data 
and there is no way to know if they were all trained to do so in exactly the same way. Additionally, it is 
not known how many separate doctors provided asthma diagnoses; that information was not available.  
BMI was also the measurement used to measure weight in this population so some 
misclassification of weight status could have occurred; yet the use of a z-score provides a standardized, 
continuous variable. Also, all patients were either overweight or obese, and nearly all were at the 90
th
 
percentile at baseline and post-intervention, therefore, misclassification of BMI category is unlikely. 
Additionally, the participants were seen many times by the same staff in a clinical setting in which both 
asthma and weight could be observed by professionals, and at the time of data collection, this study had 
not been designed yet, therefore, asthma cases and controls without asthma did not exist as defined for 
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this study. Although there are many issues with the use of retrospective secondary data, the probability of 
differential misclassification being problematic in this particular study is likely quite low (Gordis, 2014). 
There were substantial missing data for certain variables in the CHC dataset, often due to the fact 
that the collection was not necessary (as with children who had normal laboratory test values at baseline), 
sometimes due to attrition, and other times it was unknown why data were missing. Variables with a great 
deal of missing data were not used in any analysis. Yet, one of the key strengths of this study is that data 
in both datasets were comprised of clinically measured variables collected by clinicians or their staff, 
thus, recall bias was likely not an issue (Gordis, 2014). 
 
Conclusion & Recommendations for Future Research 
 This study has found that in Nevada, pediatric obese asthmatics have more severe asthma, and 
though it is not statistically significantly more severe, it may be clinically important. Overweight and 
obese youth with asthma also had higher odds of requiring oral steroids for asthma control than healthy 
weight peers. In addition, overweight and obese asthma patients were sensitized and polysensitized to 
aeroallergens, though the odds of atopy were lower in those who were overweight. 
 Finally, in evaluating a 12-week intervention program for those at risk for heart disease, 
overweight and obese children with asthma did not have higher rates of attrition than their overweight and 
obese peers without asthma. Additionally, there were no significant differences between BMI decrease or 
cardiorespiratory health increase between the two groups, although completion of the program produced 
both decreased BMI and increased cardiorespiratory health in both groups. 
  Future research is needed to determine how atopy affects pediatric obese asthmatics in climates 
where allergens are so common, such as in Nevada. Research on a larger scale, such as with a bigger 
sample size of obese children with asthma should be conducted. Studies on steroid medication in 
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overweight asthmatic children are also needed. Very little research exists regarding the use of ICS in 
obese asthmatic youth, and the consequences of decreased ICS effectiveness, such as the requirement of 
more emergency medication or oral steroids. Longitudinal research on weight loss in overweight children 
with asthma would be valuable to examine how symptoms improve over time, and with age. Obesity and 
asthma, in youth and adults, is a topic that produces new literature daily; any future recommendations for 
research may already be in progress, and all literature that contributes to this body of work could 
potentially be beneficial to children who suffer from asthma and obesity. 
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APPENDIX 1 
Body Mass Index Growth Charts  
by Sex and Age (0-20 years)  
 
Figure 4.  Length for Age and Weight for Age Percentiles for Boys, Aged Birth to 36 Months (from: 
http://www.cdc.gov/growthcharts/data/set1clinical/cj41c017.pdf) 
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Figure 5.  Length for Age and Weight for Age Percentiles for Girls, Aged Birth to 36 Months (from: 
http://www.cdc.gov/growthcharts/data/set1clinical/cj41c018.pdf) 
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Figure 6.  Body Mass Index for Age Percentiles for Boys Aged 2 to 20 (from: 
http://www.cdc.gov/growthcharts/data/set1clinical/cj41c023.pdf ) 
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Figure 7.  Body Mass Index for Age Percentiles for Girls Aged 2 to 20 (from: 
http://www.cdc.gov/growthcharts/data/set1clinical/cj41c024.pdf) 
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APPENDIX 2 
 
Table 25. Northern Nevada Allergens Used in Skin Prick Tests by the Reno Clinic 
Type of Allergen Specific Allergen 
Molds Alternaria 
 Aspergillus 
 Penicillium 
 Cladosporium 
 Dreschlera 
 Curvularia 
 Mold Mix II 
 Smuts 
Weeds (pollen producing) Pigweed 
 Sagebrush 
 Plantain 
 Dock 
 Ragweed 
 RG Mix 
 Marsh elder 
 Russian thistle 
 Rabbitbrush 
 Saltbush 
Inhalants Dermatophagoides farina (dust mite) 
 Dermatophagoides pteronyssinus (dust mite) 
 Cat 
 Dog 
 Mouse 
 Cockroach 
 Ant 
 Housefly 
 Moth 
 Rhodotorula 
Grass (pollen producing) Timothy 
 Brome 
 Bermuda 
 Saltgrass 
 Johnson 
 Alfalfa 
Trees (pollen producing) Pecan 
 Juniper 
 Alder 
 Oak 
 Elm 
 Ailanthus 
 Willow 
 Locust 
 Cottonwood 
 Birch 
 Maple 
 Privet 
 Aspen 
 Olive 
 Sycamore 
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 Pine 
 Walnut 
 Sweet Gum 
 Mulberry 
 Ash 
Animals  Horse 
 Hamster 
 Gerbil 
 Guinea Pig 
 Feather 
 Rabbit 
 Cattle 
 Goat 
 Hog 
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APPENDIX 3 
Children’s Heart Center  
Healthy Hearts Program Data Intake Form 
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Figure 8. Healthy Hearts Program Patient Information Form (page 1) 
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Figure 9. Healthy Hearts Program Patient Information Form (page 2) 
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